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ABTS*+  2,2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) radical 
AC(s)  acylcarnitine(s) 
AODS  antioxidant defense system 
BMI  body mass index 
C4DC carnitine – C4-dicarboxylcarnitine 
CARN  carnitine 
CAT  catalase 
CK(s)  cytokine(s)  
CoA  coenzyme-A 
COX-1  cyclooxygenase 1 
COX-2  cyclooxygenase 2 
CPT-1  palmitoyltransferase 1 
CrAT  carnitine acetyl-CoA transferase 
CRP  C-reactive protein 
CS(s)  control subject(s) 
FA  fatty acid 
FAO  fatty acid oxidation 
FEP  first-episode psychosis 
FEPa  first-episode psychosis patients after treatment 
FEPb  first-episode psychosis patients at the baseline (before treatment) 
GLM  general linear model 
Gpx  glutathione peroxidase 
GSH  reduced glutathione 
GSSG oxidized glutathione 
H2O2  hydrogen peroxide 
HbA1c  glycated hemoglobin 
ICD-10  International Classification of Diseases, Tenth Edition 
IFN(s)  interferon(s) 
IFN-γ  interferon gamma 
IgE  immunoglobulin E 
IL(s)  interleukin(s) 
LCAC(s) long-chain acylcarnitine(s) 
LOD  level of detection 
MDA  malondialdehyde 
Met methionine 
Met-SO  methionine sulfoxide, oxidized methionine 
MHC  major histocompatibility complex 
MitoDys  mitochondrial dysfunction 
NK natural killer 
NO  nitric oxide 
O2•−  superoxide radical 
OH•  hydroxyl radical 
ONOO•  peroxinitrite 
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OSI  oxidative stress index 
OxS  oxidative stress 
PAI-1  plasminogen activator inhibitor-1 
PANSS  Positive and Negative Syndrome Scale 
PLA2  phospholipase A2 
PON1  paraoxonase 1 
RBC  red blood cell 
RNS  reactive nitrogen species 
RO  lipid alkoxyl radical 
ROO  lipid peroxyl radical 
ROOH  lipid hydroperoxide 
ROS  reactive oxygen species 
RS  reactive species 
SCAC(s)  short-chain acylcarnitine(s) 
SCZ  schizophrenia 
sIL-2R  soluble interleukin 2 receptor 
SOD  super oxide dismutase 
TAC  total antioxidative capacity 
TAS  total antioxidant status 
TBARS  thiobarbituric acid reactive substances 
TCA  tricarboxylic acid cycle 
TGF(s)  transforming growth factor(s) 
TGF-β  transforming growth factor beta 
TNF(s)  tumor necrosis factor(s) 
TNF-α  tumor necrosis factor alpha 
TPX  total peroxide 




Schizophrenia (SCZ) has long been a part of human history, but as a discrete 
mental illness SCZ was first described in 1887 by the German physician Emil 
Kraepelin, who used the term “dementia praecox” (early dementia) and believed 
that this was primarily a disease of the brain and specifically a form of 
dementia. The term for schizophrenia is slightly over 100 years old, when the 
Swiss psychiatrist Eugen Bleuler introduced it for the first time in 1911, being 
also the first to describe “positive” and “negative” symptoms. Since then, the 
definition of SCZ has continued to evolve and nowadays it includes broader 
symptom classes which are most commonly referred to as positive, negative, 
cognitive and affective symptoms; however, to date, the diagnosis of the disease 
is still based mainly on personal and thus subjective interviews and identi-
fication of symptom clusters by a psychiatrist.  
SCZ is a chronic form of psychotic illness that starts with first-episode 
psychosis (FEP) which requires rapid medical intervention and is considered an 
important diagnostic pillar of this mental illness. Psychosis is a complex of 
symptoms accompanying SCZ that includes symptoms such as disorganized 
thought, speech and behaviour, psychomotor retardation and/or agitation. The 
onset of psychosis is usually preceded by many years of different underlying 
biological processes (Kahn & Sommer 2015) resulting among others in an 
increased pro-inflammatory and pro-oxidative status (Song et al. 2009; Girgis et 
al. 2014). The roots of metabolomic imbalance are still being studied, but 
increasingly more scientists agree on the fact that the imbalance contributing to 
psychosis is present before the onset of first psychotic episode and the start of 
pharmacological treatment (Song et al. 2014).  
Metabolomics is a large-scale study of low molecular weight metabolites 
within cells or biofluids that reflect the underlying biochemical activity and state 
of cell/tissue, biological fluid, organ or organism in general. Metabolomics 
provides an integrated picture of genomic, transcriptomic and proteomic variation 
in accordance with physiological and environmental factors that together reflect 
the functional status of individuals. Quantifiable differences in metabolite 
patterns provide valuable hints for understanding the mechanism of the disease 
and for developing diagnostic biomarkers for mental disorders (Quinones & 
Kaddurah-Daouk 2009).  
Metabolomic studies in SCZ patients have identified disturbances of several 
metabolic pathways, such as glycose, lipid, amino acid metabolism and imbalance 
redox status (Bitanihirwe & Woo 2011; Wu et al. 2013; Lee et al. 2011). The 
latter is closely linked to a variety of pathophysiological processes, such as 
inflammation, lipid peroxidation, mitochondrial dysfunction, etc., leading to an 
altered homeostasis and metabolic syndrome. The finding that metabolic 
disorder is interconnected with low-grade systemic inflammation which, in turn, 
is closely related to oxidative stress (OxS), has given ground for the research that 
resulted in the current thesis. Multiple studies have been formerly carried out on 
patients with chronic SCZ but metabolomic data available on antipsychotic-
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naïve FEP patients as they go through their first psychotic episode are limited 
and often contradictory. Metabolomic profiling of drug-naïve FEP patients may 
give valuable information by enabling exclusion of the effects of treatment and 
examination of shifts in metabolite levels during the first course of anti-
psychotic treatment.  
Currently, both clinical studies and treatment strategies are aimed to target 
the early prevention and intervention in psychotic conditions, allowing to anti-
cipate better recovery and providing a more hopeful view on the prognosis for 
early treated patients. However, one of the obstacles so far has been the 
relatively subjective diagnostic modality that may result in a considerable error 
rate due to the complex spectrum of symptoms and their similarity to symptoms 
of several mental disorders (Keller et al. 2011). In the light of these facts, it is 
relevant to explore the molecular mechanism and to develop objective diag-
nostic biomarkers for SCZ, which would not only improve our understanding of 
the disease but would also enable to diagnose the disease in its early stage and 
lead to efficient and specific therapies. Therefore, the current thesis was aimed 
to obtain information about lipidomics, inflammation and OxS status in FEP 
patients and to compare changes in the metabolomic status within the FEP 
patients’ group before and after seven-month antipsychotic treatment. 
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2. REVIEW OF LITERATURE 
2.1. General overview of schizophrenia 
SCZ is a complex, heterogeneous and severe psychiatric illness affecting about 
1% of the population (National Institute of Mental Health- NIMH 2015) and is 
considered one of the top 15 leading causes of disability worldwide (Steel 
2016). SCZ includes distinct (but often co-existing) symptom classes within the 
same person at different phases of the illness, which are commonly referred to 
as:  
• Positive symptoms that contain perceptual disturbances of reality, such as 
hallucinations (including visual and auditory, as well as other sensory per-
ceptions without any real stimulus), delusions (false beliefs with strong 
conviction), thought disorders (such as bizarre thoughts, suspiciousness and 
paranoia), movement disorders (catatonia or agitated body movements) and 
disorganized thoughts, speech and behaviour, 
• Negative symptoms that include social and emotional withdrawal from 
every-day life, low energy, apathy and anhedonia, poor self-care, absent or 
blunted or incongruous emotional responses, lethargy and lack of interest in 
activities and people,  
• Affective or mood symptoms – e.g. symptoms of mania, depression, mood 
swings, suicidal thoughts or behaviour, anxiety, guilt, irritability, and  
• Cognitive symptoms that are typically characterized by prominent specific 
deficits in memory and learning, in working memory (handling of new and 
stored information), in executive functions (planning, decision making, 
reasoning and problem solving and flexible shifting of goals), attention, 
processing speed, and social cognition which are evident on a background of 
a generalized cognitive deficit (Dickinson et al. 2008; Tandon et al. 2009; 
Howes & Kapur 2014; Millan et al. 2016).  
From the clinical and research aspect of the disease, it is reasonable to 
differentiate between prodromal phase, FEP and chronic phase of SCZ. 
 
 
2.1.1. Prodromal phase of schizophrenia 
Typically, the prodrome is characterised by nonspecific sleep disruption, mood 
and anxiety disorder symptoms, negative symptoms, attenuated positive 
symptoms and/or brief self-limiting psychotic symptoms, as well as cognitive 
dysfunctionality (Yung et al. 1996; Yung & McGorry 1996; Fusar-Poli et al. 
2014; Kahn & Sommer 2015; Conus 2010; Millan et al. 2016). Velthorst et al. 
(2013) indicate that chronic low functioning due to psychosocial stressors, lack 
of social support, maladaptive adaption skills and/or another mental disorder, 
such as depression may be an indicator of upcoming SCZ-spectrum disorder 
and can contribute to the onset of psychosis in a vulnerable person. Notable 
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deterioration in social and occupational functioning is definitely part of the 
prodromal phase of SCZ. When evaluating the prodromal period in terms of the 
risk for psychotic disorder, it appears that in general about one third of ultra-
high risk cases convert to psychosis, about one third do not develop but remain 
symptomatic with functional impairment and about one third recover functionally 
and symptomatically (Gee & Cannon 2011). Häfner and Maurer et al. (1995) 
have identified two stages in the early course of the disease that are relevant for 
identifying the risk and providing intervention: a) pre-psychotic prodromal 
stage, from the first sign of the illness to the first psychotic symptom, with an 
average duration of 4.8 years (median 2.33 years); b) psychotic pre-phase, from 
the first positive symptom to the first admission, with an average duration of 1.3 
years (median 0.8 years).  
 
 
2.1.2. First-episode psychosis 
Approximately 15% of patients with SCZ and other psychoses experience their 
FEP before the age of 18 (Amminger et al. 2011), but it is most commonly 
experienced around 18–35 years of age (Davies et al. 2017). Early onset of the 
disease can cause more developmental impairment, show greater severity of 
negative symptoms and increase the risk of some negative results compared to 
patients with delayed onset (Ballageer et al. 2005; Joa et al. 2009; Diaz-Caneja 
et al. 2015). 
Psychosis includes a set of clinical signs associated to positive symptomato-
logy of SCZ: hallucinations and delusions; detachment from reality; psycho-
motor anomalies, such as catatonia or agitation; compromised insight, and 
disorganized thinking, speech and behaviour. Psychosis is generally used as the 
operational definition of transition to SCZ-spectrum disorders, despite its less 
systematic occurrence in other disorders (Millan et al. 2016). According to Millan 
et al. (2016), full-blown positive symptoms during the first episode of psychosis 
are considered the diagnostic pillar of SCZ. 
Breitborde et al. (2009) have clarified the operational definition of FEP 
through three main categories: (i) identification of the first (antipsychotic) 
treatment contact; (ii) establishment of the duration of antipsychotic medication 
use; and (iii) identification of the duration of psychosis. Although there is no 
complete consensus on this definition, it allows harmonizing the concept of this 
stage of schizophrenia spectrum disorders and adjusting the subset of patients 
for clinical research.  
Studying of FEP patients enables exclusion of the effects of psychotropic 
medications and acquisition of more information on the pathogenetic mechanisms 
of the disease since FEP is associated with important changes in the structure 
and functioning of the brain. The way FEP is managed and treated may play an 
important role in the clinical presentation and outcome of the disease course. 
Therefore, the current thesis is focused on patients with FEP. 
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2.1.3. Chronic phase of schizophrenia 
With the exception of a minority of patients who only suffer one psychotic 
episode, those with chronic SCZ will be at risk of psychotic crises throughout 
their lives (Millan et al. 2016). The results of longitudinal studies indicate that 
about one third of patients will have experienced a relapse within one year after 
recovery and two thirds of the remaining patients before two years. Seventy to 
eighty percent of patients experience relapses within three to five years (Linszen 
et al. 2001). There is some evidence that with recurrent episodes of psychosis, 
the time to obtain response increases and the proportion of patients achieving 
remission decreases. Psychotic relapse and incomplete recovery are factors 
leading to the chronic phase of the disease (Pawełczyk et al. 2015). The long-
term outcome of the disease is also affected by the number of relapses and the 
quality of remission achieved (Emsley et al. 2013). 
It is assumed that there are specific pathophysiological processes underlying 
various symptoms of SCZ and it has been found that several neurotransmission 
pathways are dysfunctional (Howes & Nour, 2016). Different hypotheses have 
been suggested to explain the origin of SCZ, including the genetic hypothesis 
(Mowry & Nancarrow, 2001; Ripke et al. 2014), dopamine hypothesis (Snyder, 
1976; Carlsson, 1988; Davis et al. 1991), glutamate hypothesis (Kim et al. 1980), 
neurodevelopment hypothesis (Weinberger, 1987; Murray & Lewis, 1987), 
inflammation hypothesis (Maes et al. 1995; Naudin et al. 1996; Lin et al. 1998; 
Fan et al. 2007; Miller et al. 2011; Kirkpatrick & Miller 2013), OxS hypothesis 
(Reddy & Yao 1996; Mahadik et al. 2003; Do et al. 2009; Zhang et al. 2010), 
and mitochondrial dysfunction hypothesis (Ben-Shachar 2002). Each of these 
hypotheses approaches the pathophysiology of SCZ from a different point of 
view with evidence from clinical and experimental studies. However, a complete 
understanding of the disease mechanism remains elusive, as not only the 
pathophysiological aspects and treatment effects vary between different phases 
of the disease, but also qualitative and quantitative differences in biomarker 
levels have been described. The focus in this thesis is limited to the early stage 
of chronic psychotic disorder, i.e. FEP. 
 
 
2.2. First-episode psychosis and different biomarkers 
Biomarkers related to pathological conditions are crucial regarding both their 
scientific and clinical impact. There are several definitions of biomarkers 
described by Ptolemy and Rifai (2010): National Institutes of Health define a 
biomarker as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmaco-
logical responses to a therapeutic intervention”; the International Program on 
Chemical Safety define a biomarker as “any substance, structure, or process 
that can be measured in the body or its products and influence or predict the 
incidence of outcome or disease” and WHO states “almost any measurement 
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reflecting an interaction between a biological system and a potential hazard, 
which may be chemical, physical, or biological can be defined as a biomarker 
and the measured response may be functional and physiological, biochemical at 
the cellular level, or a molecular interaction” (http://www.inchem.org/ 
documents/ehc/ehc/ehc155.htm, International Programme on Chemical Safety – 
IPCS). Despite all such detailed definitions, biomarkers can be divided into 
common/routine and more specific/indicative. It is obvious that studies targeted 
to find out more indicative possible biomarkers have the potential to translate 
from “bench to bedside”.  
Regarding psychosis, including FEP, one important and growing area of 
contemporary research is focused on identification of circulating lipidomics-, 
inflammation- and OxS-related indicative biomarkers, including novel ones. In 
summary, such information gathered from patients with FEP before and after 
antipsychotic treatment and compared to the information gathered from control 
subjects (CS) may elucidate some new aspects considering both the patho-
genesis of FEP and treatment effects (positive and negative) in order to work 
out better clinical strategies in the future. 
 
 
2.2.1. First-episode psychosis and lipidomics 
Lipidomic studies are conducted to help determine the biochemical mechanisms 
of lipid-related disease processes by detecting changes in cellular lipid metabo-
lism, trafficking and homeostasis. In this thesis, the focus on lipidomics is 
specifically targeted to acylcarnitines (ACs), since there are very limited data 
available on the ACs profile in FEP patients. It is known that SCZ is associated 
with elevated fasting total triglycerides and insulin resistance (Suvisaari et al. 
2007), but this metabolic abnormality has generally been attributed to specific 
side effects of antipsychotic drugs (Meyer et al. 2008). Studies on treatment-
naïve FEP patients have already detected impaired glucose tolerance, and 
elevated insulin and metabolic abnormalities (van Nimwegen et al. 2008; 
Fernandez-Egea et al. 2009; Steiner et al. 2010; Guest et al. 2010; Guest et al. 
2011; Kirkpatrick et al. 2012) which are not caused by poor health habits 
(Kirkpatrick et al. 2012).  
ACs (from short-chain to long-chain, from C2 to C18) are the intermediates 
of the fatty acid β-oxidation process and are formed, using carnitine (CARN), to 
maintain the balance between free and esterified coenzyme-A (CoA), which is 
relevant for normal cell function. ACs are produced via transfer of the acyl 
group of a fatty acyl-CoA to L-carnitine by carnitine transferases. L-carnitine is 
relevant for transporting activated long-chain fatty acids from cytosol into 
mitochondria where oxidation of fatty acids occurs. After transport through the 
mitochondrial membrane, the acyl-CoA is converted to ACs by carnitine 
palmitoyltransferase 1 (CPT-1) (Coleman et al. 2002). CPT-1 is one of the most 
important regulators of long-chain fatty acid oxidation (McGarry et al. 1977). In 
the mitochondrial matrix, CPT-2 re-converts ACs back into free CARN and 
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long-chain acyl-CoA that can proceed to oxidation (Ramsay et al. 2001). The 
ACs which are transported through the cell membrane circulate in plasma. The 
physiological role of the ACs efflux to plasma is not completely known, but the 
formation of ACs prevents CoA from being trapped and therefore enables 
continuation of CoA dependent metabolic processes (Lopaschuk et al. 1994).  
Biochemical analysis of serum/plasma ACs helps detect inheritable disorders 
of fatty acid oxidation (FAO) enzymes. The latter tend to accumulate due to 
metabolic dysfunction of β-oxidation and tricarboxylic acid cycle in mito-
chondria (Mihalik et al. 2010). Plasma ACs levels generally vary due to 
increases in long-chain ACs (LCACs) levels, which are usually a result of 
problematic FAO (Mihalik et al. 2010; Muoio & Koves 2007). In addition to 
using LCACs as biomarkers, a variety of studies support the hypothesis that 
LCACs can activate pro-inflammatory signalling pathways (Kouttab & Simone, 
1993; Rutkowsky et al. 2014; McCoin et al. 2015a, b) and have implications for 
insulin resistance (Mihalik et al. 2010; Schooneman et al. 2013). Muoio and 
colleagues (Muoio & Koves 2007; Koves et al. 2008; Muoio & Neufer 2012) 
proposed an alternative mechanism in which FAO rate exceeds the tricarboxylic 
acid cycle (TCA), leading to the accumulation of intermediate metabolites such 
as ACs, which can interfere with insulin sensitivity.  
The concept of lipotoxicity is usually associated with the obesity-induced 
impairment of insulin sensitivity, and increasingly more attention is paid to 
intra-mitochondrial changes and impairments in FAO, thereby focusing on ACs 
(Muoio & Koves, 2007). Evidence shows that ACs have distinct functions in 
mitochondrial lipid metabolism. The trans-membrane export of ACs suggests 
that they not only prevent the accumulation of noxious acyl-CoAs but also 
release CoA from being trapped, which is relevant for the regulation of many 
metabolic pathways (Lopaschuk et al. 1994; Ramsay et al. 2001). In addition, 
the metabolism of short-chain ACs (SCACs) and the interaction of acetyl-CoA 
and ACs via carnitine acetyl-CoA transferase (CrAT) may regulate the pyruvate 
dehydrogenase complex and thus influence glucose oxidation (Muoio et al. 
2012). Besides for mitochondria the need to release CoA and export acetyl-
CoA, ACs may simply reflect the FAO flux. 
In previous studies, special attention is paid to the shortest AC, acetyl-
carnitine, due to the controlling role of acetyl-CoA on substrate switching and 
thus metabolic flexibility. The mitochondrial enzyme CrAT converts acetyl-
CoA to membrane permeable acetylcarnitine and allows mitochondrial outflow 
of excess acetyl-CoA that otherwise could inhibit pyruvate dehydrogenase 
(Muoio et al. 2012). In contrast to lower CrAT expression in diabetic subjects, 
plasma ACs levels showed significant positive correlation with glycated 
hemoglobin (HbA1c) levels over a wide range of insulin sensitivity, indicating 
an increase in CrAT activity in insulin-resistant states (Adams et al. 2009).  
Metabolomic studies have found the evidence that branched-chain and 
aromatic amino acids (isoleucine, leucine, valine, tyrosine, and phenylalanine) 
(Fiehn et al. 2010) are significantly correlated with present or future diabetes 
(Newgard et al. 2009; Fiehn et al. 2010; Wang et al. 2011). In accordance with 
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the latter, branched-chain amino acid-derived C3- and C5-carnitine, together 
with FA-derived C6- and C8-carnitine, tend to be higher in obese and type 2 
diabetes mellitus subjects compared with lean controls (Mihalik et al. 2010; 
Newgard et al. 2009). In the same study, C4-dicarboxylcarnitine (C4DC-
carnitine), which is also formed during branched-chain amino acid metabolism, 
indicated positive correlation with basal glucose levels and HbA1c (Mihalik et 
al. 2010). 
Long-chain FAs (such as palmitic acids) are linked to insulin resistance and 
making the role for LCACs such as C16 in insulin resistance supposable 
(Holland et al. 2007; Samuel & Shulman 2012). In comparison with lean 
controls, obese and insulin-resistant people had higher plasma LCACs levels 
(Mihalik et al. 2010) and after insulin infusion, there was a decrease in overall 
LCACs, but to a lesser extent in diabetic patients. This is consistent with lower 
resting energy expenditure and indicates ongoing FAO or lipid flux (metabolic 
inflexibility) (Mihalik et al. 2010). Moderate correlations between ACs profiles 
and different clinical characteristics (i.e., higher body mass index (BMI), basal 
free FA levels, insulin sensitivity) indicate a causal relationship. The more 
insulin-sensitive the subjects are, the more capable they are at metabolizing 
FAs. Thus, ACs with longer chain lengths are associated with insulin resistance, 
which seems to coincide with the known effects of long-chain FAs on insulin 
signalling. ACs can also be found in cell membranes due to their amphipathic 
nature. Longer chain length promotes merging into the membrane phase (e.g., 
C16- and 18-carnitine) (Ho et al. 2002). By contrast, ACs appear to be tracked 
with higher lipid flux and as such may only refer to higher FAO. 
The whole set of ACs has not been studied in FEP patients’ population 
before, however, studies on SCZ and FEP have shown that psychotic disorders 
change the composition of brain lipids and lipid homeostasis, which may be 
affected by antipsychotics as well (Kaddurah-Daouk & Krishnan et al. 2009; 
Polymeropoulos et al. 2009; McEvoy et al. 2013). The alterations in the whole 
ACs profile in FEP remain to be elucidated; however, as their metabolism is 
interrelated to a variety of other processes (e.g. glycose oxidation, insulin sensi-
tivity, metabolic syndrome and pro-inflammatory changes.), it may provide 
relevant insight to the pathogenesis of FEP.  
 
 
2.2.2. First-episode psychosis and inflammation 
The profile of inflammatory biomarkers can be related to the clinical status of 
the FEP patient (Miller et al. 2011; Kirkpatrick & Miller 2013) and change in 
this profile may be related to the therapeutic effect of antipsychotic treatment 
(Kirkpatrick & Miller 2013; Fond et al. 2015; Lai et al. 2016). Numerous 
studies have found that there is an imbalance of inflammatory biomarkers in the 
chronic phase of SCZ (Kirkpatrick & Miller 2013) as well as in FEP (Miller et 
al. 2011; Fond et al. 2015). Studies on treatment-naïve FEP patients show an 
increase in peripheral pro-inflammatory biomarkers and, at the same time, these 
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results are not influenced by the effects of antipsychotic treatment (Miller et al. 
2011; Kirkpatrick & Miller 2013; Fond et al. 2015). However, no final con-
sensus has been achieved over which pro- and anti-inflammatory proteomics 
biomarkers or their combinations are involved in the signature of FEP.  
Cytokines (CKs) include a large number of predominantly pro-inflammatory 
proteins, such as interleukins (ILs), interferons (IFNs), tumor necrosis factors 
(TNFs), transforming growth factors (TGFs), and chemokines, which are 
involved in the regulation of immunologic and inflammatory responses in 
physiologic and pathologic conditions (Steinke & Borish 2006). It has also been 
found that CKs regulate dopaminergic and serotoninergic neurotransmission 
(Felger & Miller 2012; Baganz & Blakely 2013). These molecules are synthe-
sized and secreted by various types of cells, including not only immune cells, 
such as T-lymphocytes, natural killer (NK) cells, monocytes/macrophages, 
polymorphonuclear leukocytes, dendritic cells, and microglia, but also non-
immune cells, such as adipocytes, neurons, fibroblasts, and endothelial cells. CKs 
coordinate the responses of cells of the innate immune system (monocyte/ 
macrophages, polymorphonuclear leukocytes, and NK cells) and those of the 
adaptive immune system (e.g., T- and B-lymphocytes). Changes in the levels of 
some CKs seem to be the main culprit of the immune and inflammatory abnor-
malities documented in SCZ and FEP (Leonard et al. 2012), and even minimal 
changes in CK levels could possibly lead to functional impairments (Altamura 
et al. 2013).  
The IL-1β, IL-2, IL-6, IL-8, IFN-γ, TNF-α are considered pro-inflam-
matory CKs, in the sense that they enhance the immune response and are 
essential to the inflammatory response by contributing to febrile response, 
activating phagocytotic cells such as macrophages, facilitating vascular per-
meability, and promoting the release of plasma-derived inflammatory mediators 
such as bradykinin and components of the complement system (Curfs et al. 1997; 
Gallin et al. 1999). The IL-10, also IL-4, IL-1 receptor antagonist (IL-1RA), and 
soluble IL-2 receptor (sIL_2R) are anti-inflammatory CKs that down-regulate 
inflammation via immunosuppressive functions (Potvin et al. 2008, Fonseka et 
al. 2016). Thus, the following brief overview focuses on the above-mentioned 
more prominent biomarkers.  
IL-6 is a pro-inflammatory CK that plays a central role in the inflammatory 
process (Chase et al. 2016; Mitra et al. 2017). The main sources of this CK are 
monocytes and macrophages at the site of injury during acute inflammation, as 
well as T-cells in chronic inflammation. In homeostatic conditions, the levels of 
IL-6 are low, but IL-6 serum levels increase rapidly with stress. Numerous studies 
have shown that IL-6 modulates various aspects of the innate immune system, 
such as hematopoiesis and influx of neutrophils at sites of infection or trauma 
(Liu et al. 1997; Chou et al. 2012). In addition, this CK induces the synthesis of 
C-reactive protein (CRP), serum amyloid A, and fibrinogen, as acute phase 
proteins (Borovcanin et al. 2017). IL-1β is released primarily by monocytes and 
macrophages, as well as by non-immune cells, such as fibroblasts and endothelial 
cells, during infection, inflammation, cell damage, and invasion (Zhang & An, 
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2007). TNF-α and IL-1 are the inducers of endothelial adhesion molecules, 
which are essential for the adhesion of leukocytes to the endothelial surface prior 
to migration into the tissues. IL-1 is the inductor of gene expression for type II 
phospholipase A2 (PLA2) and cyclooxygenase 2 (COX-2). IL-1 induces the 
transcription of COX-2 and has apparently little effect on increasing cyclo-
oxygenase 1 (COX-1) production (Dinarello 2000). TNF-α is a multifunctional 
pro-inflammatory CK, with effects on lipid metabolism, insulin resistance, 
endothelial function, and coagulation. TNF-α, a pro-inflammatory CK, is pro-
duced by many types of cells, including lymphocytes, macrophages, fibroblasts 
and keratinocytes, in response to infection, inflammation, and other types of 
environmental stress. IL-8 is a prototypical chemokine and the neutrophil 
chemoattractant, which also activates neutrophils for degranulation and causes 
tissue damage (Dinarello 2000). Biologically active IFN-γ is produced by 
mitogen activated T-lymphocytes and natural killer cells and its primary 
function is involvement in the regulation of immunological functions that are 
essential in protecting the host against viral and some bacterial and protozoal 
infections (Schoenborn & Wilson 2007). IFN-γ is an important activator of 
macrophages and induces the expression of Class II major histocompatibility 
complex (MHC) molecule. Aberrant expression of IFN-γ is associated with 
several auto-inflammatory and autoimmune diseases. The importance of IFN-γ 
in the immune system partly derives from its ability to inhibit viral replication 
directly and, most importantly, from its immunostimulatory and immunomodu-
latory effects. 
CKs, such as IL-4, IL-10, IL-13, and transforming growth factor beta (TGF-β) 
inhibit the production of IL-1, TNF-α, chemokines such as IL-8, and vascular 
adhesion molecules (Dinarello 2000). IL-10 is a CK with highly potent anti-
inflammatory properties (Murray 2006) and able to inhibit the expression of 
other inflammatory CKs such as TNF-α, IL-6 and IL-1 by activated macro-
phages. In addition, IL-10 can up-regulate endogenous anti-cytokines and down-
regulate pro-inflammatory cytokine receptors. Thus, it can counter-regulate the 
production and function of pro-inflammatory cytokines at multiple levels 
(Zhang & An 2007). Therefore, loss of IL-10 function can cause excessive and 
often damaging inflammation (Murray 2006). IL-4 regulates humoral and 
adaptive immunity, stimulates B-cells and T-cells and influences the differen-
tiation of B-cells into plasma cells, and is a key CK in the initiation of a type-2 
inflammatory response, i.e. production of immunoglobulin E (IgE) antibodies 
(Borovcanin et al. 2013). IL-4 is a CK with potent anti-inflammatory properties, 
supressing the expression of inflammatory CKs such as TNF-α, IL-6 and IL-1 
by activated macrophages. 
Among other inflammatory biomarkers, the role of ferritin, CRP and plas-
minogen activator inhibitor-1 (PAI-1) in FEP remains to be evaluated. Ferritin 
is an iron-binding molecule that stores iron in a bioavailable form and is widely 
acknowledged as a non-specific acute-phase reactant and inflammatory marker 
(Sharif et al. 2018). Serum ferritin is also a well-known inflammatory marker, 
and abnormally high serum ferritin levels are a consequence of cell stress and 
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damage (Kell & Pretorius 2014). It has been proved that inflammation and OxS 
increase the synthesis of ferritin in multiple cells, including macrophages (Sharif 
et al. 2018). CRP is an acute-phase protein of hepatic origin, which increases 
after IL-6 secretion by macrophages and T-cells. It is a trustworthy marker of 
subclinical and systemic inflammatory conditions (Windgassen et al. 2011) and 
a common final denominator in the inflammation cascade (Lopresti et al. 2014). 
It has also been associated with metabolic dysregulation, since it is synthesized by 
the liver in response to factors released by macrophages (Pepys & Hirschfield, 
2003) and fat cells (adipocytes) (Lau et al. 2005) and is widely observed in 
patients with SCZ (Vuksan-Cusa et al. 2010; Vuksan-Cusa et al. 2013). PAI-1, 
also known as an endothelial plasminogen activator inhibitor, is a protein that at 
elevated levels is a risk factor for thrombosis and atherosclerosis as it inhibits 
fibrinolysis. PAI-1 is produced mainly by the endothelium, but it can also be 
secreted by adipose tissue or other tissues. The level of PAI-1 is increased in 
metabolic syndrome but also in inflammatory conditions where fibrin is deposited 
in tissues, as it appears to favour the progression of fibrosis. (Vaughan 2005) 
Various studies on medication-naïve FEP patients have described the up-
regulation of peripheral IL-1β, IL-6, and TNF-α levels (Akiyama 1999; van 
Kammen et al. 1999; Theodoropoulou et al. 2001; Sirota et al. 2005; Na & Kim 
2007; Kim et al. 2009; Song et al. 2009), but later meta-analyses report the 
elevation of IL-1β, IL-6, IL-12, IFN-γ, TNF-α, TGF-β, interleukin 2 receptor 
(IL-2R), soluble IL-2R levels, and IL-17 (Fond et al. 2015; Fraguas et al. 2017). 
Although the elevation of TNF-α (Fond et al. 2015, Fraguas et al. 2017) and  
IL-6 has been the most repeated finding in FEP, lack of consistency in the 
results of CKs have been noted by many authors (Kronfol & Remick 2000; 
Muller et al. 1999; Gladkevich et al. 2004). Decreased levels of IL-1β and IFN-γ, 
and increased levels of IL-12 and sIL-2R have been reported after antipsychotic 
administration (Tourjman et al. 2013; Crespo-Facorro et al. 2012; MacDowell 
et al. 2013). Decreased IL-6 levels, elevated levels of IL-10, and normalization 
of T helper 17 cells were all associated with positive treatment response (Upthe-
grove et al. 2014; Kubistova et al. 2012; de Witte et al. 2014; Ding et al. 2014).  
Considering the above-mentioned inflammation-related markers, our group 
also established that FEP patients have significantly higher levels of IL-4 and 
IL-6 and significantly reduced levels of IL-1β before the start of antipsychotic 
treatment, in comparison with control subjects (Haring et al. 2015). The 
circulating levels of IL-2, IL-6, IFN-γ, IL-4, IL-8 and IL-1α were significantly 
lower in treated FEP patients compared to medication-naïve subjects (Haring et 
al. 2015). Antipsychotic treatment resulted in a significant clinical improvement 
of FEP and suppression of positive symptoms was in correlation with decreased 
levels of IL-2 and IL-4 but was accompanied with a significant increase in the 
BMI (Haring et al. 2015).  
The most plausible conclusion is that there is a chronic, low-grade inflam-
matory change related to FEP and that effective treatment significantly alleviates 
these changes. However, there still exist some inconsistencies regarding the 
selection of inflammatory biomarkers specific for FEP.  
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2.2.3. First-episode psychosis and oxidative stress 
Several studies support the understanding that both susceptibility to OxS and 
the status (level) of OxS may underlie the pathogenesis of SCZ via some 
mechanisms (Ng et al. 2008). Deterioration in schizophrenic illness is partly 
contributed by OxS (Mahadik & Scheffer 1996; Mahadik et al. 2001; Michel et 
al. 2004; Yegin et al. 2012). OxS refers to an abnormal increase in free radicals 
and reactive oxygen species (ROS), highly reactive molecules that are generated 
from metabolism – including neurotransmitters associated with SCZ such as 
dopamine and glutamate – and environmental exposures that increase an im-
balance in the pro-oxidant/antioxidant levels, leading to potential cell damage 
(Flatow et al. 2013). Free radicals are unstable atoms or molecules containing 
an odd (unpaired) electron(s) in the outer orbit, which can initiate a toxic chain 
reaction in the cell membrane or important cellular components, including DNA 
(Patel et al. 2017). The most common free radicals in a biological system are 
radical derivatives of oxygen (ROS) and nitrogen (reactive nitrogen species – 
RNS, “nitrosative stress”).  
The most important ROS in humans are hydrogen peroxide (H2O2), 
superoxide radical (O2•−), and hydroxyl radical (OH•). Mitochondria, but also 
endoplasmic reticulum and peroxisomes, are notable contributors in generating 
ROS (Patel et al. 2017). RNS include nitric oxide (NO) and peroxinitrite 
(ONOO•) (Bitanihirwe & Woo 2011). Other biologically important free radicals 
include lipid hydroperoxide (ROOH), lipid peroxyl radical (ROO•), and lipid 
alkoxyl radical (RO•), which are associated with membrane lipids. Thiol radical 
has an unpaired electron on the sulfur atom that is responsible for the formation 
of the deoxyribonucleic acids, but thiyl intermediates are also produced by the 
oxidation of glutathione (GSH) (Kurutas 2016). 
Decreased levels of antioxidants and increased production of reactive species 
(RS) will ultimately lead to oxidative damage to macromolecules such as proteins 
and lipids, nucleic acids, as well as changes in modulation of the intracellular 
signalling pathway, gene expression and deleterious changes in the activity of 
critical cellular enzymes (e.g. caspases), which can lead to cell death (Halliwell 
2006a; Cai et al. 1998; Evans et al. 2004; Scherz-Shouval & Elazar 2007; 
Pawełczyk et al. 2017). Lipid peroxidation is a well-characterized effect of ROS 
that causes damage to the cell membrane, as well as to the membranes of 
cellular organelles, such as mitochondria (Pawełczyk et al. 2017). 
Fortunately, there are several cellular antioxidant defence mechanisms to 
counterbalance the production of ROS and RNS, including enzymatic and non-
enzymatic pathways (Nordberg & Arner 2001). Biological systems have 
developed complex protection strategies against free radical toxicity. Under 
physiological conditions, the potential for free radical damage is kept under 
control by the antioxidant defence system (AODS) containing a series of enzy-
matic and non-enzymatic components that act cooperatively at different sites in 
the free radical pathways. A dynamic state is kept in check during the redox 
coupling under normal conditions (Yao et al. 2006).  
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Antioxidant enzymes that constitute the important defence system in our 
body against OxS include catalase (CAT), glutathione peroxidase (Gpx) and 
super oxide dismutase (SOD) that block the chain reaction of RS (Halliwell, 
2006a, b). In purine catabolism, xanthine oxidase catalyzes the conversion of 
xanthine to uric acid, which is an important antioxidant, and also generates 
superoxide radicals that are catalysed by SOD to hydrogen peroxide (Flatow et 
al. 2013). Both CAT and Gpx participate in the conversion of hydrogen 
peroxide to water and oxygen, but Gpx is also able to eliminate an excess of 
ROOH. GSH is a crucial non-enzymatic antioxidant in the cells. During 
elimination of RS, GSH is converted to oxidized glutathione (GSSG) by Gpx. 
Gpx also converts nitrate (a by-product of NO radicals) to nitrite that is often 
used as a marker for NO activity (Flatow et al. 2013). Hydroxyl radicals, pro-
duced from both hydrogen peroxide and NO, contribute to lipid peroxidation, 
protein carbonylation, DNA damage, and apoptosis. Vitamin E (α-tocopherol), 
acting as an antioxidant, can inhibit lipid peroxidation. In turn, the resulting 
vitamin E radicals can be recycled by vitamin C. Thiobarbituric acid reactive 
substances (TBARS), being important end products of lipid peroxidation, 
measure endogenous malondialdehyde (MDA) (Flatow et al. 2013).  
The status of OxS signature involves the levels of several biomarkers such as 
total anti-oxidative status, OxS index, lipid peroxidation and protein-related 
(e.g. the ratio of methionine sulfoxide to methionine) biomarkers. Therefore, to 
establish the status of OxS, several biomarkers should be measured simul-
taneously.  
Data on the status of OxS in SCZ and FEP are controversial. Several studies 
have documented alterations in antioxidant enzymes in SCZ, but this is not 
always consistent. While reduced levels of the antioxidant enzymes are generally 
reported in patients with SCZ compared to controls (Dadheech et al. 2008; 
Singh et al. 2008; Raffa et al. 2009), other studies have reported either no 
change (Srivastava et al. 2001) or an improvement in antioxidant status in SCZ 
(Kuloglu et al. 2002; Dakhale et al. 2004; Kunz et al. 2008). Zhang et al. 
(2010) reported findings of increased NO and TBARS in patients with SCZ. 
Both of these are involved in the oxidative degradation of lipids, affect polyun-
saturated fatty acids, and thereby damage the cell membranes, implicating lipid 
messenger signalling and DNA structure. In the same meta-analyses, the same 
authors reported the activities of SOD to be significantly decreased in dis-
organized SCZ patients, which supports the theory that the alteration of the OxS 
and mitochondrial function might underlie the pathophysiology of SCZ (Zhang 
et al. 2010). Flatow et al. 2013 explored OxS markers in patients with early 
stage of SCZ and reported reduced levels of antioxidants – total antioxidant 
status (TAS) as well as plasma nitrite and uric acid, plasma nitrites, red blood 
cell (RBC) catalase, and SOD in RBC – in patients with FEP, but on the other 
hand, significantly increased levels of plasma TBARS, MDA, and SOD in FEP 
patients versus CS. The levels of TBARS coincide with the findings by Zhang 
et al. (2010), except for the levels of plasma SOD. Recently it was shown that 
changes in some OxS markers (lipid or protein oxidation or nitric oxide 
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production) were insignificant in FEP patients compared to CS (Noto et al. 
2015). The major findings of the meta-analysis performed by Noto et al. (2015) 
revealed that FEP is accompanied by decreased paraoxonase 1 (PON1) and 
increased total radical-trapping antioxidant parameter (TRAP) levels as com-
pared to CS, and that treatment with risperidone increases PON1 and decreases 
ROOH levels. TRAP levels are determined by the effects of some specific non-
enzymatic antioxidants in the plasma, including uric acid, albumin, bilirubin, 
protein-bound thiol groups, and vitamins E and C (Halliwell, 1996). Thus, in 
theory, the elevation in TRAP in FEP patients may indicate an increase in any 
of these analyses that determine TRAP. It is possible that the increase in TRAP 
is an early compensatory process, which may counterbalance the increase in 
ROS production. These results are not in line with those of a previous meta-
analysis showing that lipid peroxidation (as measured with TBARS) and NO are 
increased in SCZ (Zhang et al. 2010).  
As seen from the results of different meta-analyses, the information regarding 
OxS parameter changes in FEP is inconsistent and in some cases contradictory 
and this issue still lacks clarity. Therefore, further studies are needed to collect 
repetitive data and gain a thorough understanding of how the OxS status may be 
related to different phases of SCZ. 
 
 
2.3. Summary of literature 
Lipidomics, inflammation and OxS are exquisitely related processes. Chronic 
low-grade inflammation is associated with elevated levels of ROS that initiate 
lipid peroxidation. And conversely, elevated OxS triggers inflammation, whereas 
redox balance inhibits the cellular response. Therefore, OxS and inflammation 
may be seen as both causes and consequences of cellular pathology in a number 
of disorders including FEP (Terlecky et al. 2012). As the results of the studies 
reveal, some aspects of lipidomics, inflammation and OxS have been investigated 
in relation to psychosis, but there are still unanswered questions or contra-
dictory data concerning the status of FEP patients. Therefore, the current thesis 
was aimed to obtain information on lipidomics (ACs), inflammation and OxS 
status in FEP patients compared to a carefully selected control group, and to 
compare the metabolomic status of FEP patients before and after seven-month 




3. AIMS OF THE THESIS 
The general aim of the study was to profile the serum levels of ACs (lipidomics), 
inflammatory and OxS biomarkers in FEP patients before and after anti-
psychotic treatment and to analyse relationships and interplay between inflam-
mation and OxS status and alterations in ACs in FEP patients.  
Specific aims: 
1. To determine the signature of ACs in patients with FEP before and after 
seven-month antipsychotic treatment, 
2. To examine the inflammatory signature in patients with FEP before and after 
seven-month antipsychotic treatment,  
3. To examine the OxS status in patients with FEP before and after seven-
month antipsychotic treatment, 
4. To summarize the bioinformation on the changes of assayed biomarkers in 




4. SUBJECTS AND METHODS 
4.1. Subjects 
4.1.1. First-episode psychosis patients 
Patients were recruited from the Psychiatry Clinic of Tartu University Hospital, 
Estonia, and 38 FEP patients (21 male and 17 female; mean age 25.4 ± 0.89 
years) gave their consent to participate in the study. In order to be enrolled, the 
patients needed to meet the following inclusion criteria: age between 18 and 
45 years; experienced FEP; duration of untreated psychosis less than 3 years; 
being antipsychotic-naïve until the first contact with medical services for 
psychosis.  
Patients were not included in the study, if they met the following exclusion 
criteria: psychotic disorders due to a general medical condition or substance 
induced psychosis. FEP was diagnosed based on clinical interviews according 
to the International Classification of Diseases, Tenth Edition (ICD-10) (World 
Health Organization 1992) criteria.  
 
 
4.1.2. First-episode psychosis patients and their treatment 
Thirty-six FEP patients out of 38 were allocated to antipsychotic treatment (two 
refused) and were included in follow-up analysis. Information on antipsychotic 
medication use was collected from patients’ medical records. The patients were 
treated according to standard of care with different antipsychotics based on the 
clinical need. During the follow-up period, the patients received either atypical 
(n=24), typical (n=1) or mixed (n=11) antipsychotic medication; the mean 
theoretical chlorpromazine dose equivalent (Gardner et al. 2010) was 396 ± 154 
(range 80–640) mg. Twenty-seven patients were treated with only 
antipsychotics, 4 patients additionally needed mood stabilizers and 6 patients 
also received antidepressants or hypnotics. During the second blood collection, 
13 patients received quetiapine (including 7 cases as only antipsychotic treat-
ment), 10 patients received aripiprazole (3 cases as only antipsychotic treatment), 
12 were treated with olanzapine (9 cases as only antipsychotic treatment), 
2 patients were assigned to risperidone (1 case as only treatment), 2 patients to 
sertindole (1 case as only antipsychotic treatment), 3 patients to ziprasidone, 
2 patients to clozapine (in both cases clozapine was administered in combi-
nation with other psychotropic drugs) and 2 patients to perfenazine (1 case as 






4.1.3. Control subjects 
The sample of CS was recruited by advertising in the same geographical area as 
the FEP patients and altogether 37 mentally healthy subjects (16 male and 21 
female, mean age 24.8 ± 0.86 years) were recruited. The CS were interviewed 
by experienced psychiatrists in order to exclude people with mental disorders. 
The exclusion criteria for the control group also included psychotic disorders 
among close relatives. Participants were enrolled between September 2009 and 
December 2013. To retain the naturalistic study design, the study participants 
were not excluded due to cigarette smoking and/or substance abuse. Eight 
patients (21.1%, all men) and 7 CS (18.9%, three of which were men) were 
active cigarette smokers. In addition, 10 patients (8 of whom were the same 
who were current cigarette smokers), and one CS (also a cigarette smoker) had 
used cannabis during his/her lifetime.  
All participants were monitored for symptoms of infections or severe 
systemic somatic illness throughout the study period. None of the study partici-
pants dropped out for that reason.  
 
 




This study consisted of two phases: the enrolment phase (on admission to 
hospital) and the follow-up phase (mean duration 7.18 ± 0.73 months). For the 
FEP patients, fasting blood samples, clinical, demographic and BMI data were 
collected at these 2 time-points. The period between enrolment and the follow-up 
phase consisted of an initial stabilization of acute psychotic symptoms (approxi-
mate duration of a month) and a further continuous six-month antipsychotic 
treatment. Symptom severity was measured using Positive and Negative 
Syndrome Scale (PANSS) (Kay et al. 1987), a rating instrument that evaluates 
the presence and severity of positive and negative symptoms and general 
psychopathology. PANSS consists of thirty items, scored from 1 (absent) to 7 
(severe) for the assessment and clinical monitoring of the course of disease and 
response to antipsychotic treatment. Physical examination included the 
evaluation of BMI [weight (kg)/ height (m)2] data. Blood samples, BMI, and 
demographic data were also collected from the CS. The study was approved by 
the Research Ethics Committee of the University of Tartu, Estonia (initial 
approval No 177/T-2 issued on 15Feb2008 and follow-up approval No 211/M-




4.2.1. Blood collection and clinical laboratory measurements  
Fasting blood samples (5 mL) from the study participants were collected into 
anticoagulant-free tubes using the standard venipuncture technique between 
9 a.m. and 11 a.m. The samples were kept for 1 hour at 4 oC (for platelet 
activation) before centrifugation at 2,000 rpm for 15 minutes at 4 oC and 
removal of serum. The serum was kept at –20 oC before testing.  
 
 
4.2.2. Measurement of biomarkers 
4.2.2.1. Measurement of acylcarnitines, methionine and  
methionine sulfoxide 
The serum levels of ACs, oxidized methionine (methionine sulfoxide, Met-SO) 
and methionine (Met) were measured with the AbsoluteIDQ™ p180 kit 
(BIOCRATES Life Sciences AG, Innsbruck, Austria) that enables detection of 
188 endogenous metabolites and 45 metabolite ratios via a combination of flow 
injection analysis and the liquid chromatograph tandem mass spectrometry 
technique. The Biocrates AbsoluteIDQ p180 kit is a commercially available 
targeted metabolomics assay and it is used in many studies of human serum and 
plasma, including clinical studies. The measurements were made according to 
the manufacturer’s manual UM-P180. Identification and quantification of the 
metabolites were achieved via monitoring multiple reactions along with internal 
standards. Of all statistically important changes of ACs, only these values were 
used that were at least 2.3 times higher than the level of detection (LOD) given 
in the manual of the Biocrates AbsoluteIDQ p180. The metabolite concent-
rations were calculated linearly using a combination of Analyst (ABSciex, 
Framingham, USA) software and MetIDQ (Biocrates Life Sciences AG, Inns-
bruck, Austria) software. To ensure the quality of data, the values were checked 
based on the LOD. The absolute minimum LOD for a metabolite is largely 




4.2.2.2. Measurement of inflammatory biomarkers 
Biochip array technology (Randox Biochip, RANDOX Laboratories Ltd, 
Crumlin, U.K., Metabolic Syndrome Array I for Evidence InvestigatorTM) was 
used to perform simultaneous quantitative detection of multiple analytes from a 
single serum sample of FEP patients or CS for inflammatory biomarkers that 
were measured according to the manufacturer’s protocol: TNF-α, IL-1α, IL-6, 
ferritin and PAI-1. Assay sensitivity varied from picograms to nanograms per 
millilitre. The reproducibility of the assay for an individual CK was determined 
using the quality controls provided with the kit (Kaur et al. 2012, Di Nicola et 
al. 2013). 
28 
4.2.2.3. Measurement of oxidative stress markers 
Measurement of total peroxide (TPX) concentration is based on the oxidation of 
ferrous ion to ferric ion by various types of peroxides. The samples were 
analysed using the OXYSTAT Assay Kit Cat. No BI-5007 (Biomedica Gruppe, 
Biomedica Medizinprodukte GmbH & Co Kg, Wien). Peroxide concentrations 
are detected based on the reaction of biological peroxides with peroxidase and 
the formation of a coloured ferric-xylenol orange complex. The absorbance of 
the latter can be measured photometrically at 450 nm, using the ELISA plate 
reader Photometer Sunrise (Tecan Austria GmbH, Salzburg). For the assay, a 
calibrator calculates the concentration of biological peroxides in the sample. 
Results show direct correlation between free radicals and circulating biological 
peroxides, thus allowing characterization of the oxidative status in biological 
samples. The concentration is stated as H2O2-equivalents (μmol/L).  
A new more stable coloured 2,2`-azinobis-(3-ethylbenzothiazoline-6-sul-
fonic acid) radical (ABTS*+) was used for the measurement of total anti-
oxidative capacity (TAC). The basic principle of the method is that a colourless 
molecule, reduced ABTS, is oxidized to a characteristic blue-green ABTS*+, 
using hydrogen peroxide in acidic solution (the acetate buffer 30 mmol/L pH 
3.6). When the coloured ABTS*+ is mixed with any reducing substance, colour-
less ABTS is formed again. The ABTS*+ is decolorized by antioxidants according 
to their concentrations and antioxidant capacities and bleaching rate is inversely 
related to the TAC of the sample. This change in colour is measured as a dif-
ference in absorbance at 660 nm. The reaction rate is calibrated with Trolox, 
which is used as a traditional standard for TAC measurement assays and the 
results are expressed in mmol Trolox equivalent/L. The within- and between-
batch precision data obtained by TAC method were 2.5% and 2.9%, respectively. 
The ratio of TPX to TAC in percentage is used as OxS index (OSI), an indicator 
of the degree of OxS (Kaldur et al. 2014). Thus, OSI was calculated according 
to the following formula: OSI = [(TPX, µmol/L): (TAC, µmol/L) x 100)].  
 
 
4.2.3. Statistical analyses  
Between-group differences in the demographic data were analysed using the  
t-test for continuous variables and chi-square test for categorical variables. The 
Shapiro-Wilk test was applied to test for normality assumption. Therefore, non-
parametric statistical methods were used to establish between- and within-group 
differences in biomarker levels. The Mann-Whitney U-test was applied to 
compare the raw data of two independent samples (FEP patients’ pre-treatment 
condition versus CS). Wilcoxon signed rank test was used for analysing OxS 
markers and Wilcoxon matched pairs test was used for ACs and inflammatory 
markers to compare two dependent samples (FEP patients before and after 
treatment). For within-subjects’ analyses, the patients were paired one by one. 
The Bonferroni correction was applied for the number of biomarkers within 
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Mann-Whitney U-test and Wilcoxon signed rank test (Miller, 1981) in order to 
diminish the likelihood of type I error. Differences between the FEP patients 
and CS (based on the Mann-Whitney U-test), and differences between the pre- 
and post-treatment values within the patient group (based on the Wilcoxon 
matched pairs test), regarding serum ACs levels, were considered statistically 
significant at p < 0.05 throughout the analyses. To demonstrate effect size (eta2) 
estimates for the non-parametric tests, the values of squared standardized test 
statistics (Z) were divided by the total number of observations on which Z was 
based. Effect sizes were interpreted as small, medium, and large, with the 
corresponding eta-squared ranging from 0.01–0.05, 0.06–0.13, and ≥0.14, 
respectively (Cohen, 1988). 
To find the correlations between OxS, low-grade inflammation and meta-
bolic markers in FEP patients’ group before and after 7-month antipsychotic 
treatment, Spearman’s rank correlation analysis was applied.  
In order to demonstrate between-group differences for biomarkers levels (i.e. 
drug-naïve FEP patient versus CS, and FEP patients after treatment versus CS) 
and within-group changes (i.e. drug-naïve FEP patients versus FEP patients 
after treatment), general linear models (GLM) were applied. The biomarker 
values were log10-transformed to approximate normality as GLM analyses re-
quired normally distributed data. Categorical (disease, gender, smoking status) 
and continuous (age) covariates were used in the GLM to compare biomarker 
and OxS levels (dependent variables) between the groups. An independent 
variable was used to study within-subjects’ differences in pre- and post-treat-
ment OxS conditions. In the next step, backward variable elimination was used 
until the best model fit was reached. Each subsequent step removed the least 
significant variable in the model until all remaining variables had individual  
p-values smaller than 0.05. F-tests were used to further compare the fits of the 
linear models and to analyse significant (disease or treatment) main effects in 
the final models. The statistical analyses were performed using the Statistica 










General characteristics of the study groups 
The studies were carried out on carefully selected FEP patients and in a CS 
group in order to exclude FEP patients with substance-induced psychosis or 
psychosis due to their general medical condition and to exclude CS with 
psychiatric disorders or among their close relatives. The application of Shapiro-
Wilk test indicated that age and BMI followed normal distributions, but the 
values of ACs, inflammatory, and OxS markers had non-normal distributions 
(p < 0.05). There were no statistically significant differences between the 
antipsychotic-naïve FEP patients and CS in terms of age (t(73 )= 0.49, p = 0.62) 
and gender (χ2(1) = 1.08, p = 0.30), or mean (± s.d.) scores of BMI (22.6 ± 2.9 and 
23.0 ± 3.1, respectively; t(73) = –0.69, p = 0.49). During the 7-month antipsychotic 
treatment, positive symptom (Z = 5.16, p < 0.000001), negative symptom 
(Z = 5.23, p < 0.000001), general symptom (Z = 5.18, p < 0.000001) and total 
symptom (Z = 5.23, p < 0.000001) scores demonstrated a significant positive 
decline. The 7-month treatment caused a significant change in BMI (t(35)= –8.07, 
p < 0.000001). Mean BMI gain at 7 months follow-up was 2.97 kg/m2 (±2.21). In 
addition, the difference in tobacco use (8 patients [21.1%] versus 7 controls 
[18.9%]) was not statistically significant (χ2(1) = 0.05, p = 0.82). 
 
 
5.1. Profiling of acylcarnitines in first-episode  
psychosis before and after seven-month  
antipsychotic treatment (Paper I) 
Based on the evident impact of ACs on lipid metabolism, FAO and insulin 
sensitivity, as well as their associations with inflammatory responses, a well-
characterized cohort of antipsychotic-naïve FEP patients and CS was used to 
profile CARN and ACs in their blood samples. 
 
 
5.1.1. Acylcarnitine profile alterations in first-episode psychosis 
patients before and after seven-month antipsychotic treatment  
The whole set of 39 ACs together with CARN were measured in FEP patients 
and CS (Table 1). Mann-Whitney U-test and Wilcoxon matched pairs test were 
first run to report differences in AC baseline levels between the groups (FEP 
patients vs. CS) and within the FEP group (before and after 7-month anti-
psychotic treatment).  
Twenty-four out of 39 ACs exhibited shifts in FEP patients at baseline 
compared to CS, but only eight of them (C14:1, C16, C16:1, C16:1-OH, C18:1, 
C18:2, C3, C6[C4:1-DC]) remained after the Bonferroni correction for multiple 
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comparisons (p ≤ 0.001) and demonstrated large effect sizes (Table 1). All of 
the above-mentioned ACs were increased, except for C3 which was decreased.  
Thereafter, the impact of treatment on ACs levels was analysed (Table 2); 
4 ACs (C16, C18:1, C18:2, C3) were statistically significant and also reflected 
large effect sizes. As a result of antipsychotic treatment, 3 out of these 4 ACs 
demonstrated a decrease in their levels, except for C3 which was increased. 
 
Table 1. Identification of differences in serum acylcarnitine levels (µmoles) between 
first-episode psychosis (FEP) patients at baseline (before treatment with antipsychotics) 
and control subjects (CS). 
Biomarkers 








































































































–3.42 0.0006 0.16 
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Biomarkers 




































































































































–2.23 0.03 0.07 
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Biomarkers 





































–2.59 0.01 0.09 
Z-adjusted values according to Mann-Whitney U-test (first-episode psychosis patients before the 
treatment compared to CS); p-values ≤0.001 after the Bonferroni correction (bold) were 
considered statistically significant. Effect sizes were interpreted as medium and large, with 
corresponding eta-squared ranging from 0.06–0.13, and ≥0.14, respectively.  
  
Table 2. Identification of differences in serum acylcarnitine levels (µmoles) between 
first-episode psychosis (FEP) patients at baseline and FEP patients after seven-month 
















































































































































2.70 0.007 0.10 
















































































































































0.93 0.35 – 
Z-values according to Wilcoxon matched pairs test (first-episode psychosis patients before the 
treatment compared to first-episode psychosis patients after the treatment); p-values less than or 
equal to 0.001 after the Bonferroni correction (bold) were considered statistically significant. 
Effect sizes were interpreted as medium and large, with corresponding eta-squared ranging from 
0.06–0.13, and ≥0.14, respectively.  
 
 
5.1.2. The profile of acylcarnitines specific for first-episode psychosis 
and seven-month antipsychotic treatment 
An alternative methodological approach (GLM) was applied to confirm the 
existence of significant main effects of the disease and treatment on the levels 
of ACs. Important co-variates (gender, smoking status, age) were included in 
the further analyses. After applying GLM, the levels of 22 ACs (and hexose) 
demonstrated statistically significant differences, and the most prominent 
difference emerged in five ACs levels (C14:1, C16, C16:1, C18:1 and C3) out 
of which 4 ACs (C14:1, C16, C16:1, C18:1) showed an increase in their levels 
and C3 showed a decrease when comparing drug-naïve FEP patients and CS 
(Table 3).  
A positive treatment effect occurred in relation to 14 ACs levels, the most 
significant among them being a decrease in C18:1 level when FEP patients were 
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compared before and after treatment (Table 4). Interestingly, no differences in 
AC levels were detected by using GLM between CS and post-treatment FEP 
patients (Table 5).  
 
Table 3. Comparison of acylcarnitine serum levels between first-episode psychosis 
(FEP) patients at baseline (before the treatment with antipsychotics) and control 
subjects (CS).  
Biomarkers ß ß (95 % CI) t-value p-value 
C0_Carnitine –0.06 –0.30, 0.17 –0.54 0.59 
C10_Decanoylcarnitine 0.32 0.09, 0.54 2.82 0.006 
C10:1_Decenoylcarnitine 0.15 –0.08, 0.39 1.28 0.21 
C10:2_Decadienylcarnitine –0.09 –0.32, 0.14 –0.80 0.43 
C12_Dodecanoylcarnitine 0.28 0.06, 0.51 2.48 0.02 
C12-DC_Dodecanedioylcarnitine –0.04 –0.26, 0.19 –0.31 0.76 
C12:1_Dodecenoylcarnitine 0.25 0.03, 0.48 2.23 0.03 
C14_Tetradecanoylcarnitine 0.30 0.08, 0.52 2.73 0.008 
C14:1_Tetradecenoylcarnitine 0.43 0.22, 0.64 4.08 0.0001 
C14:1-OH_Hydroxytetradecenoylcarnitine 0.29 0.06, 0.52 2.55 0.01 
C14:2_Tetradecadienylcarnitine 0.39 0.17, 0.61 3.56 0.0007 
C14:2-OH_Hydroxytetradecadienylcarnitine 0.004 –0.23, 0.24 0.03 0.98 
C16_Hexadecanoylcarnitine 0.48 0.28, 0.69 4.63 0.00002 
C16-OH_Hydroxyhexadecanoylcarnitine 0.25 0.02, 0.48 2.19 0.03 
C16:1_Hexadecenoylcarnitine 0.55 0.36, 0.74 5.81 0.000001 
C16:1-OH_Hydroxyhexadecenoylcarnitine 0.41 0.20, 0.62 3.93 0.0002 
C16:2_Hexadecadienylcarnitine 0.18 –0.06, 0.41 1.52 0.13 
C16:2-OH_Hydroxyhexadecadienylcarnitine –0.12 0.36, 0.12 –1.02 0.31 
C18_Octadecanoylcarnitine 0.33 0.11, 0.56 2.93 0.005 
C18:1_Octadecenoylcarnitine 0.57 0.37, 0.76 5.77 0.000001 
C18:1-OH_Hydroxyoctadecenoylcarnitine 0.20 –0.04, 0.43 1.70 0.09 
C18:2_Octadecadienylcarnitine 0.42 0.21, 0.63 3.93 0.0002 
C2_Acetylcarnitine 0.18 –0.04, 0.40 1.65 0.10 
C3_Propionylcarnitine –0.46 –0.67, –0.26 –4.51 0.00003 
C3-DC(C4-OH)_Malonylcarnitine 
(Hydroxybutyrylcarnitine) 
0.35 0.13, 0.57 3.14 0.003 
C5-OH(C3-DC-M)_Hydroxyvalerylcarnitine 
(Methylmalonylcarnitine) 
0.08 –0.15, 0.31 0.70 0.49 
C3-OH_Hydroxypropionylcarnitine –0.02 –0.26, 0.22 –0.19 0.86 
C3:1_Propenoylcarnitine 0.07 –0.17, 0.30 0.54 0.59 
C4_Butyrylcarnitine –0.36 –0.58, –0.15 –3.33 0.001 
C4:1_Butenylcarnitine 0.21 –0.02, 0.44 1.80 0.08 
C6(C4:1-DC)_Hexanoylcarnitine 
(Fumarylcarnitine) 
0.42 0.20, 0.64 3.83 0.0003 
C5_Valerylcarnitine –0.30 –0.52, –0.08 –2.69 0.009 
C5-DC(C6-OH)_Glutarylcarnitine 0.23 0.004, 0.45 2.03 0.046 
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Biomarkers ß ß (95 % CI) t-value p-value 
(Hydroxyhexanoylcarnitine) 
C5-M-DC_Methylglutarylcarnitine 0.05 –0.18, 0.29 0.45 0.66 
C5:1_Tiglylcarnitine 0.01 –0.23, 0.25 0.09 0.93 
C5:1-DC_Glutaconylcarnitine 0.18 –0.05, 0.40 1.53 0.13 
C6:1_Hexenoylcarnitine 0.14 –0.09, 0.38 1.20 0.24 
C7-DC_Pimelylcarnitine 0.22 –0.01, 0.45 1.91 0.06 
C8_Octanoylcarnitine 0.25 0.02, 0.48 2.19 0.03 
C9_Nonaylcarnitine –0.37 –0.59, –0.15 –3.32 0.001 
H1_Hexose 0.28 0.06, 0.50 2.49 0.02 
ß: regression coefficients; CI: confidence intervals; p-values (derived from GLM analysis); 
significance of log10-transformed values in acylcarnitine levels in the disease, adjusted for gender, 
age and smoking status. Significant t-values (p < 0.05) are marked in bold. 
 
 
Table 4. Effects of seven-month treatment with antipsychotics on metabolite levels 
among the first-episode psychosis (FEP) patient group.  
Biomarkers ß ß (95 % CI) t-value p-value 
C0_Carnitine 0.08 –0.24, 0.40 0.52 0.61 
C10_Decanoylcarnitine 0.21 –0.09, 0.50 1.40 0.17 
C10:1_Decenoylcarnitine 0.06 –0.24, 0.36 0.40 0.69 
C10:2_Decadienylcarnitine 0.09 –0.21, 0.39 0.61 0.54 
C12_Dodecanoylcarnitine 0.27 –0.02, 0.56 1.87 0.07 
C12-DC_Dodecanedioylcarnitine –0.16 –0.47, 0.15 –1.03 0.31 
C12:1_Dodecenoylcarnitine 0.17 –0.13, 0.47 1.11 0.27 
C14_Tetradecanoylcarnitine 0.38 0.09, 0.67 2.64 0.01 
C14:1_Tetradecenoylcarnitine 0.41 0.14, 0.68 3.02 0.004 
C14:1-OH_Hydroxytetradecenoylcarnitine 0.34 0.05, 0.64 2.32 0.02 
C14:2_Tetradecadienylcarnitine 0.41 0.13, 0.69 2.94 0.005 
C14:2-OH_Hydroxytetradecadienylcarnitine 0.23 –0.08, 0.53 1.48 0.15 
C16_Hexadecanoylcarnitine 0.47 0.20, 0.74 3.44 0.001 
C16-OH_Hydroxyhexadecanoylcarnitine 0.29 –0.01, 0.59 1.91 0.06 
C16:1_Hexadecenoylcarnitine 0.44 0.19, 0.70 3.42 0.001 
C16:1-OH_Hydroxyhexadecenoylcarnitine 0.43 0.15, 0.71 3.06 0.003 
C16:2_Hexadecadienylcarnitine 0.31 0.02, 0.61 2.10 0.04 
C16:2-OH_Hydroxyhexadecadienylcarnitine –0.16 –0.47, 0.16 –0.99 0.33 
C18_Octadecanoylcarnitine 0.38 0.08, 0.68 2.51 0.02 
C18:1_Octadecenoylcarnitine 0.55 0.31, 0.80 4.47 0.00003 
C18:1-OH_Hydroxyoctadecenoylcarnitine 0.33 0.04, 0.63 2.25 0.03 
C18:2_Octadecadienylcarnitine 0.47 0.20, 0.74 3.51 0.0008 
C2_Acetylcarnitine 0.03 –0.27, 0.32 0.17 0.87 
C3_Propionylcarnitine –0.39 –0.68, –0.10 –2.66 0.01 
C3-DC(C4-OH)_Malonylcarnitine 0.38 0.10, 0.66 2.71 0.009 
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0.07 –0.24, 0.38 0.48 0.64 
C3-OH_Hydroxypropionylcarnitine 0.14 –0.17, 0.45 0.90 0.37 
C3:1_Propenoylcarnitine 0.16 –0.16, 0.47 1.00 0.32 
C4_Butyrylcarnitine –0.17 –0.49, 0.14 –1.12 0.27 
C4:1_Butenylcarnitine 0.23 –0.08, 0.55 1.50 0.14 
C6(C4:1-DC)_Hexanoylcarnitine 
(Fumarylcarnitine) 
0.29 –0.01, 0.59 1.99 0.05 
C5_Valerylcarnitine –0.27 –0.57, 0.03 –1.79 0.08 
C5-DC(C6-OH)_Glutarylcarnitine 
(Hydroxyhexanoylcarnitine) 
0.27 –0.02, 0.56 1.88 0.07 
C5-M-DC_Methylglutarylcarnitine 0.17 –0.14, 0.48 1.10 0.28 
C5:1_Tiglylcarnitine 0.06 –0.25, 0.37 0.42 0.68 
C5:1-DC_Glutaconylcarnitine 0.12 –0.18, 0.42 0.80 0.43 
C6:1_Hexenoylcarnitine 0.03 –0.27, 0.33 0.20 0.84 
C7-DC_Pimelylcarnitine 0.28 –0.02, 0.58 1.89 0.06 
C8_Octanoylcarnitine 0.16 –0.14, 0.46 1.06 0.29 
C9_Nonaylcarnitine –0.19 –0.49, 0.11 –1.26 0.21 
H1_Hexose 0.17 –0.13, 0.48 1.13 0.26 
ß: regression coefficients; CI: confidence intervals; p-values (derived from GLM repeated 
measure); significance of log10-transformed values in acylcarnitine levels in the patient group 
before treatment compared with the biomarker values measured after 7-month treatment with 
antipsychotics, adjusted for gender, and smoking status. Significant t-values (p < 0.05) are marked 
in bold. 
 
Table 5. Metabolite levels in first-episode psychosis (FEP) patients after seven-month 
treatment with antipsychotics compared to control subjects (CS). 
Biomarkers ß ß (95 % CI) t-value p-value 
C0_Carnitine –0.11 –0.34, 0.13 –0.93 0.36 
C10_Decanoylcarnitine –0.03 –0.27, 0.20 –0.29 0.77 
C10:1_Decenoylcarnitine –0.03 –0.26, 0.21 –0.22 0.83 
C10:2_Decadienylcarnitine –0.16 –0.39, 0.08 –1.35 0.18 
C12_Dodecanoylcarnitine –0.10 –0.33, 0.13 –0.84 0.40 
C12-DC_Dodecanedioylcarnitine –0.02 –0.26, 0.23 –0.14 0.89 
C12:1_Dodecenoylcarnitine –0.05 –0.29, 0.19 –0.40 0.69 
C14_Tetradecanoylcarnitine –0.16 –0.39, 0.08 –1.31 0.20 
C14:1_Tetradecenoylcarnitine –0.10 –0.33, 0.13 –0.89 0.38 
C14:1-OH_Hydroxytetradecenoylcarnitine –0.11 –0.34, 0.13 –0.92 0.36 
C14:2_Tetradecadienylcarnitine –0.16 –0.38, 0.07 –1.40 0.17 
C14:2-OH_Hydroxytetradecadienylcarnitine –0.22 –0.45, 0.02 –1.86 0.07 
C16_Hexadecanoylcarnitine –0.03 –0.27, 0.20 –0.28 0.79 
C16-OH_Hydroxyhexadecanoylcarnitine 0.07 –0.17, 0.31 0.59 0.56 
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Biomarkers ß ß (95 % CI) t-value p-value 
C16:1_Hexadecenoylcarnitine 0.003 –0.24, 0.24 0.02 0.98 
C16:1-OH_Hydroxyhexadecenoylcarnitine 0.06 –0.19, 0.30 0.45 0.65 
C16:2_Hexadecadienylcarnitine –0.18 –0.42, 0.05 –1.59 0.12 
C16:2-OH_Hydroxyhexadecadienylcarnitine –0.08 –0.31, 0.16 –0.63 0.53 
C18_Octadecanoylcarnitine 0.001 –0.24, 0.24 0.01 0.99 
C18:1_Octadecenoylcarnitine –0.07 –0.31, 0.17 –0.61 0.54 
C18:1-OH_Hydroxyoctadecenoylcarnitine –0.03 –0.26, 0.21 –0.23 0.82 
C18:2_Octadecadienylcarnitine –0.08 –0.31, 0.14 –0.74 0.46 
C2_Acetylcarnitine 0.13 –0.10, 0.36 1.11 0.27 
C3_Propionylcarnitine –0.08 –0.31, 0.16 –0.64 0.53 
C3-DC(C4-OH)_Malonylcarnitine 
(Hydroxybutyrylcarnitine) 
–0.01 –0.24, 0.23 –0.04 0.97 
C5-OH(C3-DC-M)_Hydroxyvalerylcarnitine 
(Methylmalonylcarnitine) 
0.07 –0.17, 0.30 0.58 0.56 
C3-OH_Hydroxypropionylcarnitine –0.02 –0.26, 0.22 0.20 0.84 
C3:1_Propenoylcarnitine 0.02 –0.21, 0.25 0.17 0.86 
C4_Butyrylcarnitine –0.22 –0.45, 0.02 –1.84 0.07 
C4:1_Butenylcarnitine 0.12 –0.11, 0.35 1.02 0.31 
C6(C4:1-DC)_Hexanoylcarnitine 
(Fumarylcarnitine) 
–0.01 –0.25, 0.23 –0.10 0.92 
C5_Valerylcarnitine –0.01 –0.24, 0.23 –0.06 0.95 
C5-DC(C6-OH)_Glutarylcarnitine 
(Hydroxyhexanoylcarnitine) 
–0.09 –0.32, 0.14 –0.76 0.45 
C5-M-DC_Methylglutarylcarnitine –0.09 –0.33, 0.15 –0.74 0.46 
C5:1_Tiglylcarnitine –0.08 –0.32, 0.16 –0.68 0.50 
C5:1-DC_Glutaconylcarnitine 0.02 –0.22, 0.26 0.15 0.88 
C6:1_Hexenoylcarnitine –0.04 –0.27, 0.20 –0.31 0.76 
C7-DC_Pimelylcarnitine –0.17 –0.40, 0.06 –1.45 0.15 
C8_Octanoylcarnitine –0.02 –0.26, 0.22 –0.15 0.88 
C9_Nonaylcarnitine –0.13 –0.37, 0.11 –1.08 0.28 
H1_Hexose 0.20 –0.03, 0.43 1.72 0.09 
ß: regression coefficients; CI: confidence intervals; p-values (derived from GLM analysis); 
significance of log10-transformed values in acylcarnitine levels in the first-episode patient group 
after 7-month treatment with antipsychotics compared to control subjects, adjusted for gender, 





5.1.3. Ratio of CARN to LCACs and SCACs  
Calculation of the ratio of CARN to LCACs and SCACs was based on raw data. 
The SCACs to CARN ratio in drug-naïve FEP patients showed a significant 
decrease in C3 (Mann Whitney U-test, Z = 4.24, p = 0.00002) and C5 (Z = 2.38, 
p = 0.018) (Figure 1), whereas, CPT-1, reflecting the ratio of LCACs to CARN, 
demonstrated increased accumulation of C14, C16, C18 (Z = 3.42, p = 0.0006). 
Treatment with antipsychotic drugs eliminated all the above-mentioned shifts. 
The levels of C3 (Wilcoxon matched paired tests, Z = 4.10, p = 0.00004) and C5 
(Z = 2.38, p = 0.017) were significantly increased compared with CARN 
(Figure 1). By contrast, CPT-1 showed a tendency of reduction in LCACs levels 
(Z = 2.19, p = 0.029) compared with CARN. 
 
 
Figure 1. The ratio of short-chain acylcarnitines (SCACs) and long-chain acylcarnitines 
(LCACs) to carnitine (CARN) in FEP patients before and after antipsychotic treatment. 
CS: control subjects; FEPb: first-episode psychosis (FEP) patients at baseline (before 
the treatment); FEPa: FEP patients after the treatment with antipsychotic drugs; CPT-1: 
the ratio of LCACs to CARN; CS versus FEPb: Mann-Whitney U-test: * – p < 0.05; 
*** – p < 0.001; FEPb versus FEPa: Wilcoxon matched pairs’ test: * – p < 0.05;  





5.2. Selected inflammatory biomarkers in first-episode 
psychosis before and after seven-month antipsychotic 
treatment (Paper II) 
This study focused on the status of selected inflammatory biomarkers (ferritin, 
IL-6, IL-1α, TNF-α, and PAI-1) in antipsychotic-naïve FEP patients at baseline 
compared to CS and analysed the change of inflammatory markers in FEP 
patients after 7-month antipsychotic treatment.  
 
 
5.2.1. Differences in the levels of selected inflammatory  
biomarkers between antipsychotic-naïve first-episode  
psychosis patients and control subjects 
The analysis of inflammatory biomarkers (Mann-Whitney U-test, raw data) 
showed a significant increase in ferritin, PAI-1, and IL-6 in antipsychotic-naïve 
FEP patients vs CS (Table 6). Based on this study sample, group differences for 
the above-mentioned biomarkers demonstrated medium effect sizes.  
 
Table 6. Comparison of selected inflammatory biomarker levels between first-episode 
psychosis (FEP) patients at baseline and control subjects (CS). 
Inflammatory 
Biomarkers 
CS FEP at baseline Z-value p-value Effect 




























2.75 0.006* 0.10 
Data presented in pg/mL as medians (range). Z-values according to Mann-Whitney U-test (FEP 
patients before treatment compared to CS).  
IL-1 α, IL-6: interleukins; TNF-α: tumour necrosis factor-α; PAI-1: plasminogen activator 
inhibitor-1; CS: control subjects.  





5.2.2. Effects of antipsychotic drugs on inflammatory biomarkers 
Seven-month antipsychotic treatment had a significant impact on several 
inflammatory biomarkers in FEP patients (Table 7) but the strongest decline 
was established for ferritin (p=0.00003), which showed a large effect. Changes 
were also revealed in the levels of IL-1α (p=0.01) as well as in IL-6 (p=0.03) 
and PAI-1 (p=0.03), which demonstrated medium-size effects in decline.  
 
Table 7. Comparison of selected inflammatory biomarkers levels between first-episode 
psychosis (FEP) patients at baseline and after 7-month treatment with antipsychotics. 
Biomarkers FEP baseline FEP after treatment Z-value p-value Effect 

























2.24 0.03 0.07 
Data presented in pg/mL as medians (range). Z-values according to Wilcoxon matched pairs test 
(FEP patients, pre- and post-treatment timepoints, respectively); IL-1 α, IL-6: interleukins; TNF-
α: tumour necrosis factor-α; PAI-1: plasminogen activator inhibitor-1. *p-values: adjusted with 
the Bonferroni correction of alpha (0.05/5 ≤ 0.01). 
 
 
5.2.3. Inflammatory biomarker levels  
in first-episode psychosis patients after seven-month treatment  
with antipsychotics compared to control subjects 
After seven-month antipsychotic treatment the most prominent decrease was 
seen in IL-1α levels, which demonstrated a medium effect size compared to  
IL-1α levels in CS (Table 8). Elevated levels of ferritin, TNF-α and PAI-1 in the 
FEP group demonstrated a considerable positive decrease as a result of 




Table 8. Comparison of inflammatory biomarker levels between control subjects (CS) 
and first-episode psychosis (FEP) patients after seven-month treatment with 
antipsychotics. 
Biomarkers CS FEP after treatment Z-value p-value Effect size ƞ2 

























0.79 0.43 – 
Data presented in pg/mL as medians (range). Z-adjusted values according to Mann-Whitney  
U-test (FEP patients after treatment compared to CS).  
IL-1 α, IL-6: Interleukins; TNF-α: tumour necrosis factor-α; PAI-1: plasminogen activator 
inhibitor- 1.  
*p-values: adjusted with the Bonferroni correction of alpha (0.05/5 ≤ 0.01). 
 
 
5.3. Oxidative stress status in first-episode  
psychosis before and after seven-month  
antipsychotic treatment (Paper III) 
This study was carried out to compare the OxS status [serum total antioxidant 
capacity (TAC), total level of peroxides (TPX), oxidative stress index (OSI), 
ratio of oxidized methionine (Met-SO) to methionine (Met)] between 
antipsychotic-naïve FEP patients and individuals without history of psychiatric 
disorders, i.e. CS.  
 
 
5.3.1. Differences in the levels of oxidative stress markers  
among antipsychotic-naïve first-episode psychosis patients and 
control subjects 
FEP patients compared to CS did not show any differences regarding OxS-
related parameters (TPX, TAC, OSI), Met-SO and Met and Met-SO/Met ratio 





Table 9. Comparison of oxidative stress markers (OxS) between first-episode psychosis 
(FEP) patients at baseline and control subjects (CS), as well as FEP patients at baseline 
and after seven months of treatment with antipsychotics.  




















































–0.98 0.33 2.05 0.04 






–0.86 0.39 2.15 0.03 
All units presented as medians (range): TAC in mmol Trolox Eq/L unit, TPX in μmol H2O2 Eq/L 
unit, OSI in percent ratio, Met and Met-SO in μmol, Met-SO/Met as ratio.  
Z-valuesA according to Mann-Whitney U-test (FEP patients before treatment compared to CS).  
Z-valuesB according to Wilcoxon matched pairs test (FEP before treatment compared to FEP after 
treatment). TAC: total antioxidant capacity; TPX: total level of peroxides; OSI: oxidative stress 
index; Met: methionine; Met-SO: methionine sulfoxide; Met-SO/Met: ratio of oxidized 
methionine to methionine. 
 
Figure 2. The changes in TPX, TAC and OSI (A) and Met, Met-SO, and Met-SO/Met 
(B) due to FEP (Wilcoxon signed rank test). FEP: first-episode psychosis; CS: control 
subjects; TAC: total antioxidant capacity; TPX: total level of peroxides; OSI: oxidative 
stress index; Met: methionine; Met-SO: methionine sulfoxide; Met-SO/Met: ratio of 
























































A multivariate GLM analysis was used to reveal the potential effect of FEP on 
the combination of OxS markers. The overall difference between the groups is 
presented in Table 10. The main effect of FEP was revealed in OSI level 
(t(5,64) = 2.26, p = 0.03, Radj
2 = 0.17) and was affected by male gender (t(5,64) = –
3.32, p = 0.001). Nevertheless, there was no statistically significant correlation 
between the group status and gender regarding OSI level. Considering the 
model-based level, there was a medium-size effect of the disease (before the 
treatment) on the OxS markers (partial ƞ2=0.13, F(5,64) = 1.9, p = 0.11). 
 
Table 10. Regression coefficients (ß) and significance of log10-transformed values of 
the oxidative stress (OxS) markers in first-episode psychosis.  
OxS markers ß ß (95 % CI) t-value p-value 
TAC  –0.13 –0.37–0.11 –1.10 0.28 
TPX 0.21 –0.02–0.43 1.82 0.07 
OSI  0.25 0.03–0.47 2.26 0.03 
Met 0.08 –0.15–0.31 0.70 0.49 
Met-SO –0.18 –0.41– 0.05 –1.58 0.12 
Met-SO/ Met –0.15 –0.37–0.08 –1.28 0.21 
ß: regression coefficients; CI: Confidence intervals; TAC: total antioxidant capacity; TPX: total 
level of peroxides; OSI: oxidative stress index; Met: methionine; Met-SO: methionine sulfoxide; 
Met-SO/Met: ratio of oxidized methionine to methionine.  
 
 
5.3.2. The effect of antipsychotic treatment on the levels  
of biomarkers in first-episode psychosis  
Comparison of FEP patients before and after seven-month antipsychotic therapy 
revealed a significant and positive decrease in TPX and OSI levels (Table 9, 
Figure 3A), as well as a positive increase in Met level and a decrease in Met-SO 
and Met-SO/Met (Table 11, Figure 3B).  
In further analyses the impact of treatment on OxS levels was evaluated. 
Repeated measures GLM was used to compare the main effects of the 7-month 
antipsychotic treatment on the concentration of serum biomarkers. The effect of 
treatment is demonstrated in Table 11. Considering all measured OxS markers, 
the levels of TAC, Met, Met-SO, and Met-SO/Met did not differ between pre- 
and post-treatment conditions, whereas a decrease over time was detected in the 
serum levels of TPX (p = 0.04), and OSI (p = 0.01). These results confirm that 
treatment with antipsychotics has a positive impact on the OxS markers’ levels 
during the early phase of the psychotic disease. The size of the effect of 




Figure 3. The changes in TPX, TAC and OSI (A) and Met, Met-SO, and Met-SO/Met 
(B) due to FEP and antipsychotic treatment. *p < 0.05 (Wilcoxon signed rank test). 
FEP: first-episode psychosis; TAC: total antioxidant capacity; TPX: total level of 
peroxides; OSI: oxidative stress index; Met: methionine; Met-SO: methionine sulfoxide; 
Met-SO/Met: ratio of oxidized methionine to methionine. 
 
Table 11. The effect of seven-month antipsychotic treatment on the oxidative stress 
(OxS) markers in the first-episode patient group.  
OxS markers ß ß (95 % CI) t-value p-value 
TAC  –0.19 –0.42–0.05 –1.56 0.12 
TPX 0.25 0.02–0.48 2.12 0.04 
OSI 0.30 0.07–0.53 2.61 0.01 
Met –0.19 –0.43–0.05 –1.62 0.11 
Met-SO 0.15 –0.10–0.38 1.21 0.23 
Met-SO/ Met 0.18 –0.06–0.42 1.51 0.14 
ß: regression coefficients; CI: Confidence intervals; significance of the log10-
transformed values for the oxidative stress (OxS) markers in the first-episode patient 
group, pre- and post-treatment timepoints; TAC: total antioxidant capacity; TPX: total 
level of peroxides; OSI: oxidative stress index; Met: methionine; Met-SO: methionine 
sulfoxide; Met-SO/Met: ratio of oxidized methionine to methionine. 
p < 0.05 values are marked in bold 
 
Furthermore, GLM was used to evaluate the FEP patients’ post-treatment status 
regarding the levels of OxS markers compared to CS (adjusted for age, gender 
and smoking status). The levels of TAC, TPX and OSI in FEP patients were 
comparable with those of CS (Table 12).  


























































On the other hand, 7-month treatment with antipsychotics caused a signi-
ficant increase in Met (p = 0.03) as well as a decrease in Met-SO (p = 0.02) and 
Met-SO/Met (p = 0.006) levels in the FEP patient group compared to CS. These 
changes were associated with the effects of age. In particular, the effect of 
treatment was significantly associated with higher Met levels in younger patients 
(t(5,63) = –3.06, p = 0.003) as well as with lower levels of serum Met-SO and 
Met-SO/Met in older patients (t(5,63) = 2.45, p = 0.02; t(5,63) = 3.14, p = 0.003, 
respectively).  
  
Table 12. The effect of 7-month antipsychotic treatment on the oxidative stress (OxS) 
markers in the first-episode patient group compared to the control subjects. 
OxS markers ß ß (95 % CI) t-value p-value 
TAC  0.02 –0.22–0.26 0.17 0.87 
TPX –0.01 –0.24–0.21 –0.12 0.90 
OSI –0.02 –0.24–0.20 –0.19 0.85 
Met  0.24 0.02–0.47 2.21 0.03 
Met-SO  –0.32 –0.54–(–0.09) –2.77 0.007 
Met-SO/ Met  –0.31 –0.53–(–0.10) –2.86 0.006 
ß: regression coefficients; CI: Confidence intervals; significance for the log10-
transformed values for the oxidative stress (OxS) markers in the first-episode patients’ 
group after treatment compared to CS; TAC: total antioxidant capacity; TPX: total level 
of peroxides; OSI: oxidative stress index; Met: methionine; Met-SO: methionine 
sulfoxide; Met-SO/Met: ratio of oxidized methionine to methionine.  
p < 0.05 values are marked in bold 
 
Spearman rank correlation established a significant positive correlation of TPX 
with IL-1β (ρ = 0.26, p = 0.03) and of TAC with IL-1β (ρ = 0.25, p = 0.04) 
among the FEP patients. After treatment, a significant negative correlation was 
found between treatment and OSI (ρ = –0.28, p = 0.02) and positive correlation 
was found between BMI and TAC (ρ = 0.31, p < 0.01).   
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6. DISCUSSION 
FEP can be seen as an intermediate state which has relevant implications for 
further clinical course, treatment and management of chronic psychotic dis-
orders. Patients need to receive the best comprehensive science-based care in 
order to achieve the best quality of remission and to avoid or to diminish the 
number of future psychoses. Among others, psychiatric disorders have been 
shown to be related to a shift in the composition of brain lipids (i.e. 
phospholipids, PUFAs) (Horrobin 1998; Horrocks LA & Farooqui 2004; Yao et 
al. 2004), inflammation (Potvin et al. 2008; de Witte et al. 2014; Miller et al. 
2011; Upthegrove et al. 2014) and OxS (Kaur & Cadenhead 2010; Noto et al. 
2015; Sarandol et al. 2015). Therefore, the general aim of this thesis was 
profiling of ACs, inflammation and OxS in FEP before and after treatment, 
specifically collecting data on the relationships between inflammation and OxS 
status and alterations in ACs in FEP.  
 
 
6.1. Acylcarnitines in first-episode psychosis before and 
after seven-month antipsychotic treatment (Paper I) 
Antipsychotic treatment is known to have an impact on patient’s body weight 
(including BMI), glycose and lipid metabolism and may also affect the profile 
of ACs. The impact of ACs on FAO, inflammation and insulin sensitivity is 
widely known (Adams et al. 2009; Mihalik et al. 2010). Therefore, altered 
mitochondrial homeostasis may change the level of ACs and their accumulation 
may indicate mitochondrial dysfunction (MitoDys) (Sampey et al. 2012; 
D’Souza et al. 2016). Consequently, it is crucial to study the contribution of 
CARN and ACs to the metabolic status of psychiatric patients (Reuter & Evans, 
2012), as according to literature, chronic treatment with antipsychotic drugs 
impacts lipid metabolism (Misiak et al. 2017; McEvoy et al. 2013; Bobo et al. 
2011; Kaddurah-Daouk & Krishnan, 2009) and it can hence also cause shifts in 
the ACs profile. It has been proposed that the plasma concentrations of ACs, 
particularly medium- and long-chain ACs, can predict the intracellular energy 
metabolism pattern and can be used as markers for metabolic dysfunction (Mai 
et al. 2013; Koves et al. 2008; Adams et al. 2009).  
Our current lipidomic profiling demonstrated shifts in 24 ACs out of 39 in 
FEP patients compared to CS, although only 8 of them (C14:1, C16, C16:1, 
C16:1-OH, C18:1, C18:2, C3, C6(C4:1-OH)) remained after the Bonferroni 
correction for multiple comparisons and showed large effect sizes. After 
applying GLM for the same sample, 5 ACs demonstrated the most prominent 
shifts. Four ACs (C14:1, C16, C16:1 and C18:1) out of 5 were significantly 
elevated and one (C3) was substantially decreased in FEP patients compared to 
CS, which would allow to make the generalization that there is a shift towards 
an increase in LCACs and a decrease in SCACs.  
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Antipsychotic treatment for 7 months caused significant alterations in 14 
metabolites in FEP patients, but only 4 ACs (C16, C18:1, C18:2, C3) remained 
after the Bonferroni correction for multiple comparisons and demonstrated large 
effect sizes. The levels of 3 of these ACs were significantly decreased (C16, 
C18:1, C18:2) and the level of C3 was significantly increased. GLM analysis 
revealed C18:1 as the only altered metabolite that showed a significant decrease 
in FEP patients after treatment. The post-treatment AC values for FEP patients 
were not significantly different from the corresponding values for CS, 
demonstrating that antipsychotic treatment enabled restoration of the values of 
ACs to the levels of CS.  
Increased levels of LCACs (particularly C16 and C18:1) (Rizza et al. 2014) 
have been associated with cellular stress (McCoin et al. 2015a), mitochondrial 
alterations, or an increase in cellular inflammation (McCoin et al. 2015b; Aguer 
et al. 2015), while decreased levels of LCACs (particularly C14:1, C16 and 
C18:1) (Fastner et al. 2018) might indicate lower cellular inflammation pro-
cesses. In general, accumulation of LCACs inhibits oxidative phosphorylation 
(Korge et al. 2003), impairs cell insulin signalling (Koves et al. 2008; Aguer et 
al. 2015), modulates cell membrane ion channels and increases membrane 
permeability. It has also been found that LCAC C18:1 at high nanomolar 
concentrations inhibits glycine transport via glycine transporter GlyT2 (related 
to the nociceptive pathways) (Carland et al. 2013). Inflammation and nocicep-
tion are long known to be interconnected and LCACs have been hypothesized 
to serve as bioactive stress signals under circumstances when their accumu-
lation is abnormally high (Adams et al. 2009; Koves et al. 2008). In addition, 
fasting plasma LCACs may be elevated in chronic metabolic diseases such as 
obesity and type 2 diabetes mellitus, although patients with diabetes may also 
have elevated levels of short- and medium-chain ACs (Sampey et al. 2012; 
Muoio et al. 2012; Aguer et al. 2015). 
The increase in LCACs in the FEP patients may indicate the presence of 
systemic low-grade inflammation, as the ratio of LCAC to CARN (CPT-1) was 
significantly shifted toward the formation of LCACs. By contrast, the ratio of 
SCACs to CARN showed reduced formation of C3 and C5 in FEP patients at 
baseline. The ratio of C3 and C5 to CARN, as well as BMI were elevated after 
continuous treatment with antipsychotic drugs for seven months. This finding 
seems to emphasize the role of SCACs in the regulation of energy metabolism 
as higher circulating concentrations of SCACs (especially C3 and C5-DC) have 
been associated with the development of type 2 diabetes (Newgard et al. 2009). 
Based on existing data, FEP patients have been shown to display some signs of 
pre-diabetes and glucose dysregulation (Foley & Morley, 2011; Henderson et 
al. 2015; Perry et al. 2016; Garcia-Rizo et al. 2017). Emerging domination of 
LCACs, mitochondrial overload and incomplete FAO start to affect insulin 
sensitivity. Due to the amphipathic nature of LCACs (C16, C18), they can 
reside in cell membranes and interfere with insulin signalling directly from the 
membrane. Changes in glucose metabolism are especially important in 
developing the risk of metabolic syndrome or type 2 diabetes. Often this can be 
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associated to the side effects of antipsychotic treatment, however SCZ was 
already found to be associated with higher rates of diabetes before the neuro-
leptic era (Kohen 2004) and a recent meta-analysis by Pillinger et al. (2017) has 
supported the understanding that alterations in glucose levels are part of the 
disease present from its onset. Another piece of evidence supports the fact that 
FEP is accompanied by disturbances in glucose utilization and energy 
production (Holmes et al. 2006; Greenhalgh et al. 2017).  
The current data from the FEP patients compared to CS also demonstrated an 
increase in hexose level which indicates potential changes in carbohydrate 
metabolism (Paper I). All these above-mentioned shifts (SCACs, LCACs, 
hexose) may evidence certain MitoDys, as the metabolism pathways of lipids, 
glucose and amino acids cross in the mitochondria.  
 
 
6.2. Selected inflammatory biomarkers in first-episode 
psychosis before and after seven-month antipsychotic 
treatment (Paper II) 
Activation of the inflammatory response system in SCZ has been noted and 
evidenced for decades and several authors have studied these findings in detail 
(Fan et al. 2007; Potvin et al. 2008; Müller and Schwarz, 2010; Drexhage et al. 
2010). Inflammatory changes have been found to be present in subjects with 
drug-naïve FEP compared to controls, suggesting that shifts in the levels of 
inflammatory biomarkers are independent of the effects of antipsychotic medi-
cations (Kirkpatrick & Miller 2013). Our current inflammatory profiling also 
supports the notion that the levels of several inflammatory biomarkers in 
antipsychotic-naïve FEP patients compared to CS are changed: the levels of 
ferritin (an acute phase protein), PAI-1 (being an important regulator of 
fibrinolysis), and IL-6 (a pro-inflammatory CK involved predominantly in 
inflammation through monocytes/macrophages and also regulating metabolic 
processes) showed a statistically significant increase in antipsychotic-naïve FEP 
patients. Elevation of the above-mentioned markers indicates possible signs of 
low-grade inflammatory processes in FEP, which is in accordance with other 
studies that have reported the elevation of IL-6 (Song et al. 2013; Di Nicola et 
al. 2013; Stojanovic et al. 2014; Upthegrove et al. 2014; Petrikis et al. 2015; 
Bocchio-Chiavetto et al. 2018), as well as ferritin and PAI-1 (Hoirisch-
Clapauch et al. 2016; Schwarz et al. 2010; Bocchio-Chiavetto et al. 2018) in 
FEP patients. Data from the literature confirm that pro-inflammatory CKs, such 
as IL-6 but also IL-1β and TNF-α, play an essential role in the modulation of 
various cerebral functions (Larson and Dunn 2001; Anisman et al. 2002) and 
enhanced peripheral and/or central pro-inflammatory CK signalling has notably 
been shown to impair affective, emotional and social functions (Dantzer et al. 
2008). Animal models have revealed that peripheral and/or central adminis-
tration of pro-inflammatory CK-releasing agents markedly induces anhedonic 
behaviour and social impairments (Anisman et al. 2002; Dantzer et al. 2008), 
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both of which have been associated with the negative symptoms of SCZ (Möller 
2007; Tandon et al. 2009). Furthermore, enhanced release of IL-6 as a result of 
peripheral inflammation has been associated with two other distinctive features 
of negative symptoms: deficiency in sustained attention (Holden et al. 2008) 
and psychomotor retardation (Brydon et al. 2008).  
There is evidence that antipsychotic drugs can modulate components of the 
inflammatory-related pathways (Meyer et al. 2008) and can also reduce the 
emerging signs of metabolic syndrome (Haring et al. 2015; Miller et al. 2011; 
Upthegrove et al. 2014). In addition, CKs have been found to regulate immune/ 
inflammatory reactions and brain development, and to influence the 
dopaminergic, serotonergic, noradrenergic, and glutamatergic neurotransmission 
(Miller et al. 2011; Watanabe et al. 2010; Müller et al. 2015). The results of our 
study on the FEP patient population indicated that 7-month antipsychotic 
treatment had an effect on several inflammatory biomarkers, but the strongest 
decline occurred in the level of ferritin, followed by IL-1α (Paper II). Anti-
psychotic treatment was also associated with a decrease in IL-6 as well as in 
PAI-1 levels, both of which demonstrated a medium-size effect, however 
considering the small group of the study patients, these results lost their validity 
after the Bonferroni correction for multiple comparisons. When comparing the 
effects of antipsychotic treatment in FEP patients to the biomarker levels in CS, 
the most prominent difference was seen in IL-1α levels, which fell below the 
corresponding levels in CS and demonstrated a medium-size effect. The levels 
of the other inflammatory biomarkers (ferritin, TNF-α and PAI-1 and IL-6) 
returned to the corresponding levels in CS. Although there is no final consensus 
on the state and trait makers of FEP and SCZ, it is evident that the peripheral 
immune system is over-activated in individuals undergoing their FEP and also 
in people suffering from chronic SCZ (Lai et al. 2016).  
Antipsychotic treatment causes significant reduction in the psychopathology 
(PANSS) total score, while its negative and obvious impact was an increase in 
BMI (a common side-effect of antipsychotic medication) (Bak et al. 2014; De 
Hert et al. 2009; McEvoy et al. 2005). This is consistent with the results of the 
present study, as the BMI values did not differ between antipsychotic-naïve 
FEP patients and CS at baseline, but the increase after the 7-month anti-
psychotic treatment was significant. There can be several reasons for such BMI 
increase. Firstly, it is a known side-effect of antipsychotic drugs (such as 
olanzapine and clozapine) (Bak et al. 2014; De Hert et al. 2009); secondly, it 
might be caused by changes in the surrounding environment of the patients, 
including everyday care. The effect of limited physical activity of patients 
cannot be neglected (De Hert et al. 2009; Rastad et al. 2014). These results are 
in accordance with a meta-analysis by Tarricone et al. (2010), which enrolled 
antipsychotic-naïve patients and reported an increase in BMI immediately after 
the first exposure to antipsychotics, particularly during the first two months, 
which continued to increase up to a year or more of treatment. In addition, Bak 
et al. (2014) reported that weight gain continues over time and is associated 
with prolonged antipsychotic use.  
52 
6.3. Oxidative stress markers in first-episode  
psychosis before and after seven-month  
antipsychotic treatment (Paper III) 
One of the mechanisms of the etiology of SCZ is the faulty antioxidant system, 
which results in increased lipid peroxides, causing membrane defects, immune 
system dysfunction and pathology of different systems of neurotransmitters in 
SCZ (Yao and Keshavan 2011). Along with abnormal inflammation, OxS is 
another pathogenic process that contributes to the poor outcome of SCZ 
(Bošković et al. 2011; Mitra et al. 2017). Elevation of plasma lipid peroxides 
has been shown to be present at the onset of psychosis in never-medicated, first-
episode SCZ patients (Mahadik et al. 1998). This suggests the presence of OxS 
already very early in the course of the illness, irrespective of treatment. In 
addition to peripheral OxS, increased neuronal OxS levels affect signal trans-
duction, structural plasticity and cellular resilience, mostly by inducing lipid 
peroxidation in membranes and direct damage to protein and genes (Gama et al. 
2007; Gama et al. 2008a; Gama et al. 2008b). Neurons and glia cells are 
particularly vulnerable to inflammatory processes and changes in the redox 
status and are dependent on maintaining neurotrophic activity (Kapczinski et al. 
2010; Kapczinski et al. 2011; Kunz et al. 2008; Kunz et al. 2011). Furthermore, 
oxidative stress has been identified as a possible element in the neuro-
pathological processes of SCZ (Riegel et al. 2010; Dietrich-Muszalska & 
Kontek, 2010; Kunz et al. 2008; Gama et al. 2008a; Gama et al. 2008b).  
In our OxS study of peripheral biomarkers, we failed to reveal significant 
differences in OxS-related parameters such as TPX, TAC, OSI and Met-SO/Met, 
when comparing FEP patients to CS. In other words, total antioxidative capa-
city, lipid peroxidation and protein-oxidation related indices did not differ in 
FEP patients before treatment compared to CS. These results are consistent with 
a study performed on FEP patients by Noto et al. 2015. According to multi-
variate GLM analysis for the potential effect of FEP on the combination of OxS 
markers, the main effect of the disease resulted in slightly increased OSI level. 
Studies by other groups have shown associations between FEP and increased 
status of OxS (Martínez-Cengotitabengoa et al. 2012; Fournier et al. 2014; 
Sarandol et al. 2015). Although the nature of OxS, whether lipid-related or 
protein-related, and the grade of OxS (low-grade, high-grade) in FEP remain 
elusive, the data of this thesis indicate that FEP could be described as an 
increase in OSI level; also, at the whole model level there was a moderate effect 
on OxS markers.  
In our study, seven-month antipsychotic treatment in FEP patients caused a 
significant decrease in TPX and OSI compared to the baseline status of the FEP 
group. Although there were no changes in lipid-related OxS, the treatment 
caused a favourable decrease in protein-related OxS by lowering the levels of 
Met-SO and Met-SO/Met and increasing the level of Met. After using repeated 
measures GLM to assess the main effects of the 7-month antipsychotic 
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treatment on serum biomarker levels, with all OxS markers taken into account, 
a decrease was detected in serum TPX and OSI; the levels of the other markers 
being similar for pre- and post-treatment timepoints. When comparing the FEP 
patients after treatment with CS, there was a significant increase in Met and a 
decrease in Met-SO and Met-SO/Met; the levels of TAC, TPX and OSI were 
comparable for both groups. 
As a result of 7-month antipsychotic treatment, there was a decrease in OxS 
status. In addition to reduced lipid peroxidation and protein oxidation related 
indices of OxS, this study also highlights improvement in the inflammatory 
status with antipsychotic treatment. Therefore, the treatment strategy in FEP 
patients needs to consider both inflammation and OxS as closely interrelated 
counterparts for the following reasons. Firstly, there exist correlations between 
inflammatory and OxS markers in FEP patients, as inflammation is associated 
with elevated levels of reactive oxygen species. Secondly, antipsychotic 
treatment significantly improves inflammatory signature in FEP patients and 
has a positive impact on the indices of OxS at the early stage of this psychotic 
disorder because anti-inflammatory cascades are related to reduced ROS 
concentrations. In addition, recent reviews and meta-analyses (Bitanihirwe & 
Woo 2011; Flatow et al. 2013; Leza et al. 2015), studying the interactions 
between inflammation and OxS, highlight their close relationship in SCZ and 
emphasize that these two may be both the causes and consequences of cellular 
pathology. 
It is appropriate to underline that the profiling of ACs also showed modi-
fications in the LCACs profile, which can reflect severity of inflammation. It 
should be noted that the seven-month treatment with antipsychotics not only 




6.4. Specific biomarkers for first-episode psychosis before 
and after antipsychotic treatment  
Our studies in FEP patients confirm the shifts in the levels of different bio-
markers that were already present before the start of antipsychotic treatment 
(Papers I–III, Figure 4). The increase in LCACs (C14:1, C16, C16:1, C18:1) 
can indicate mitochondrial dysfunction, cellular stress or cellular inflammation. 
This assumption is supported by the fact that FEP patients also demonstrated 
increased levels of the non-specific acute-phase inflammatory marker ferritin, 
pro-inflammatory CK IL-6 and PAI-1. The elevated levels of PAI-1 have been 
found to be present in metabolic syndrome (Hoirisch-Clapauch et al. 2016; Jung 
et al. 2018; Bocchio-Chiavetto et al. 2018). The ratio of SCACs to CARN 
showed reduced formation of C3 and C5 in antipsychotic-naïve FEP patients, 
whereas the formation of LCACs prevailed. Increased levels of LCACs have 
been found to inhibit energy metabolism and impair insulin signalling of the 
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cells (Koves et al. 2008; Muoio et al. 2012; Noland et al. 2009; Adams et al. 
2009; Sampey et al. 2012). 
Seven-month antipsychotic treatment had several favourable impacts on the 
levels of metabolic, inflammatory and OxS biomarkers. Shifts in LCACs and 
SCACs as well as the levels of selected inflammatory biomarkers were reversed 
and returned to the corresponding levels in CS. Treatment also increased the 
level of SCAC and caused an elevation in the ratio of C3 and C5 to CARN. The 
status of low-grade inflammation also improved as evidenced by a marked 
decline in ferritin and IL-1α levels. The decline in the latter dropped lower than 
IL-1α level in CS. OxS markers also showed reduced indices of lipid peroxida-
tion and protein oxidation. In general, antipsychotic treatment appears to have a 
positive impact on low-grade inflammation and OxS, in addition to a significant 
amelioration in psychotic symptoms. On the other hand, chronic exposure to 
antipsychotic treatment may have an impact on glucose dysregulation as 
elevation in C3 and C5-DC levels has been associated with the development of 
type 2 diabetes mellitus (Newgard et al. 2009).  
 
Figure 4. Changes in biomarkers due to FEP before and after seven-month anti-
psychotic treatment, summarizing the current results presented in this thesis. FEP: first-
episode psychosis; LCACs: long-chain acylcarnitines (C14:1, C16, C16:1, C18:1, 
C18:2); SCACs: short-chain acylcarnitines (C3, C5); TPX: total level of peroxides; 
OSI: oxidative stress index; Met: methionine; Met-SO: methionine sulfoxide; Met-
SO/Met: ratio of oxidized methionine to methionine; IL-1α, IL-6: interleukins; PAI-1: 
plasminogen activator inhibitor-1; BMI: body mass index.  
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Chronic treatment with antipsychotics seems to lead to pre-diabetic state. There 
was also a significant increase in BMI compared to its baseline levels in the 
patients. This has been associated with the side effects of antipsychotic drugs, 
but it can also be related to the sedentary lifestyle of SCZ patients compared to 
the general population (De Hert et al. 2009; Rastad et al. 2014). In conclusion, 
treatment of FEP is associated with metabolic changes and future therapies 
should concentrate on solutions that can avoid or minimize unwanted changes 




The results of this thesis enable to state the following:  
1. The serum levels of LCACs (C14:1, C16, C16:1 and C18:1) were elevated 
and the level of SCAC (C3) was decreased in FEP patients compared to CS. 
Antipsychotic treatment returned the shifts in ACs to the corresponding level 
in CS, with the most marked decline seen in C18:1, and also reversed the 
decline in SCACs (C3 and C5) levels. The balance in the formation of 
SCACs (C3, C5) and LCACs via CARN was shifted to the formation of 
LCACs, which probably indicates low-grade inflammation in FEP patients. 
At the same time, antipsychotic treatment also decreased the level of 
inflammation. 
2. Antipsychotic-naïve FEP patients had elevated serum levels of ferritin,  
PAI-1 and IL-6 compared to CS. As a result of seven-month antipsychotic 
treatment, the most prominent decline was seen in ferritin level, followed by 
the decrease in IL-1α in FEP patients. Compared to CS, the decline in IL-1α 
exceeded the level of CS. The levels of ferritin, TNF-α, PAI-1 and IL-6 
returned to the corresponding levels in CS as a result of antipsychotic 
treatment, while the obtained data also support the fact that FEP is associated 
with low-grade inflammation and treatment (7 months) has a positive impact 
by reducing inflammation.  
3. Antipsychotic-naïve FEP patients did not show any significant differences in 
OxS-related parameters such as TPX, TAC, OSI and Met-SO/Met when 
compared to CS. In the FEP patient group, seven-month treatment with 
antipsychotics reduced the rates of protein and lipid oxidation, decreased the 
levels of TPX and OSI, and demonstrated also a significant increase in Met 
and a decrease in Met-SO and Met-SO/Met levels. Compared to CS, there 
were no statistically significant differences in the levels of TAC, TPX and 
OSI in FEP patients after treatment. Although the baseline results did not 
demonstrate a significant increase in OxS levels in FEP patients compared to 
CS, antipsychotic treatment had a positive effect by shifting the OxS levels 
below the values seen in controls.  
4. Figure 4 shows the detailed signature of FEP in view of the change in low-
grade inflammation, lipidomics (the referred ACs) and OxS status before and 
after seven-month treatment. As a result of seven-month antipsychotic 
treatment, the biomarker profile of FEP patients did not differ from that of 
the controls. Nevertheless, the enhanced formation of SCACs, supported by 
the increase in BMI, triggered impaired insulin processing, insulin resistance 
and metabolic syndrome, causing undesirable metabolic shifts at an early 
stage of the disease. Consequently, our comprehensive study of FEP high-
lights the efficiency of treatment at the molecular level, but also indicates 
that future treatment strategies should be improved to minimize the risk for 
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SUMMARY IN ESTONIAN 
Atsüülkarnitiinide, põletiku ja oksüdatiivse stressi määra kajastavate 
biomarkerite profiilid esmase psühhoosiepisoodiga patsientidel enne 
ja pärast antipsühhootilist ravi 
Skisofreeniaspektri häired avalduvad esmase psühhootilise episoodiga enamasti 
noores täiskasvanueas. Psühhoosi puhul võivad kliinilises pildis ilmneda eri-
nevad sümptomid, mis on iseloomulikud ka skisofreeniale, nagu näiteks  
taju-, mõtlemis-, tunde- ja tahteelu häired. Psühhootiliste häirete põhjus on 
bioloogiliste protsesside häirumine ajus, mis on tihedalt seotud organismi 
üldiste metaboolsete muutusega, sh ka põletiku ja/või oksüdatiivse stressi 
markerite muutusega. Varasemad uuringud kinnitavad, et skisofreeniaspektri 
häired ja metaboolne sündroom ühes suhkru- ja lipiidide ainevahetushäiretega 
on omavahel tihedalt seotud. Samas puudub ühtne seisukoht, et kuivõrd meta-
boolne düsregulatsioon krooniliste psühhootiliste häirete puhul on omistatav 
haigusele enesele või antipsühhootlise ravi kõrvalmõjudele. Antud küsimusele 
võimaldab vastuseid pakkuda esmase psühhoosiepisoodiga patsientide vere-
seerumist eraldatavate biomarkerite tasemete uurimine enne antipsühhootlise 
ravi alustamist ja ravi kohaldamise järgselt.  
Esmase psühhoosiepisoodiga patsientidel läbiviidud uuringud on leidnud 
glükoosi taluvuse langust, insuliini taseme tõusu ning metaboolseid muutusi 
juba enne ravi algust antipsühootikumidega. Atsüülkarnitiinid on rasvhapete 
beetaoksüdatsiooni vaheproduktid, mille lagundamise tulemusena mitokond-
riaalses maatriksis tekivad ketokehad. Atsüülkarnitiinide biokeemiline analüüs 
võimaldab määrata mitokondrite funktsiooni ning rasvhapete oksüdatsiooniga 
seotud ensüümide häireid, kuna see põhjustab pikaahelaliste atsüülkarnitiinide 
kuhjumist verre, mis omakorda aktiveerib põletikumediaatorite vabanemist ning 
mõjutab insuliini resistentsuse teket. Põletikumarkerite profiil võib olla seotud 
patsiendi kliinilise staatusega ja muutused selles võivad olla seotud anti-
psühhootilise ravi toimega. Samas on muutusi põletikumarkerite tasemes tähel-
datud nii kroonilise skisofreenia kui ka emase psühhoosiepisoodiga patsientidel, 
kes pole veel antipsühhootilist ravi saanud. Põletikumarkereid sekreteerivad 
organismis erinevad rakud, mis on seotud immunoloogilise ja põletikulise 
vastuse tekkega füsioloogilistes ja patoloogilistes tingimustes. Tsütokiinide 
hulka kuuluvad erinevad põletikku vahendavad valgud nagu interleukiinid, 
interferoonid, tuumornekroosifaktorid, transformeerivad kasvufaktorid ja kemo-
kiinid. Antipsühhootiline ravi omab positiivset mõju haigussümptomitele ning 
lisaks tekitab muutusi põletikumarkerite profiilis, alandades üldist põletiku 
taset. Erinevate uuringute tulemusena pole aga teadlased leidnud konsensust, 
millised on konkreetsed skisofreenia või esmase psühhootilise episoodiga 
seotud verest määratavad diagnostilised põletikumarkerid ja millised muutused 
biomarkerite tasemetes haiguse erinevates staadiumites aset leiavad. 
Oksüdatiivse stressi puhul saavutavad prooksüdandid (reaktiivsed hapniku, 
lämmastiku osakesed ja vabad radikaalid, nagu lipiidide peroksüül- ja alkok-
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süülradikaalid jt) ülekaalu antioksüdantide üle ning sellest tekkiv redoksstaatuse 
muutus põhjustab rakkude kahjustust, patofüsioloogilisi protsesse nagu põletik, 
lipiidide peroksüdatsioon, mitokondrite düsfunktsionaalsus jt, mis tekitavad 
muutusi organismi homöostaasis. Oksüdatiivse stressi staatuse hindamiseks 
tuleb mõõta mitmeid biomarkereid. Paraku on andmed oksüdatiivse stressi 
olemasolu kohta skisofreeniaspektri häire erinevate staadiumite puhul vastu-
rääkivad. Mitmed uuringud on raporteerinud muutustest antioksüdantsete 
ensüümide osas, kuid oksüdatiivse stressi allika (lipiidide või valkude perok-
südatsioonist tingitud) ja määra (low-grade, high-grade) osas on uuringu-
tulemused olnud varieeruvad.  
Psühhootiliste häirete puhul on kaasaegsete uuringute ja kliiniliste ravistra-
teegiate rakendamise eesmärk varajane ennetamine ja/või sekkumine, mis aitab 
kaasa haiguse paremale prognoosile ja toetab paranemist. Erinevate psühhooti-
liste häirete sümptomite sarnasus ning komplekssus muudab aga diagnoosimise 
keerukaks. Eelnevat arvesse võttes on oluline uurida psühhootiliste haiguste 
molekulaarseid mehhanisme ja raviga kaasnevaid muutusi ning töötada välja 
objektiivsed diagnostilised biomarkerite paketid, mis võimaldaks skisofreenia-
spektri häireid diagnoosida haiguse varasemas staadiumis, häire olemust 




Antud doktoritöö üldine eesmärk oli uurida atsüülkarnitiinide profiili, põletiku 
ja oksüdatiivse stressi taseme määra ning osakaalu esmase psühhoosiepisoodiga 
patsientidel enne ja pärast antipsühhootilist ravi ning analüüsida andmeid 
põletiku ja oksüdatiivse stressi taseme ning atsüülkarnitiinide muutuste kohta 
seitsmekuulise antipsühhootilise ravi jooksul. 
Uuringu täpsemad eesmärgid: 
1. selgitada, millised on muutused atsüülkarnitiinide tasemetes esmase psüh-
hoosiepisoodiga patsientidel enne ja pärast seitsmekuulist antipsühhootilist 
ravi; 
2. määrata põletikumarkerite tase esmase psühhoosiepisoodiga patsientidel enne 
ja pärast seitsmekuulist antipsühhootilist ravi; 
3. selgitada, milline on oksüdatiivse stressi osakaal esmase psühhoosiepi-
soodiga patsientidel enne ja pärast seitsmekuulist antipsühhootilist ravi; 
4. määratleda üldised muutused mõõdetud biomarkerite lõikes esmase psüh-
hoosiepisoodiga patsientidel enne ja pärast seitsmekuulist antipsühhootilist 
ravi. 
 
Uuritavad ja meetodid 
Uuringu läbiviimine oli kooskõlastatud Tartu Ülikooli inimuuringute eetika 
komiteega ning kõik uuritavad andsid kirjaliku informeeritud nõusoleku uurin-
gus osalemiseks. Uuritavaid patsiente oli kokku 38 (21 meest ja 17 naist) ning 
nad olid pöördunud esmase psühhoosiepisoodi avaldumise järgselt ravile Tartu 
75 
Ülikooli Kliinikumi Psühhiaatriakliinikusse. Uuringusse kaasamiseks pidid 
patsiendid vastama järgmistele kriteeriumitele: vanus 18–45 eluaastat; esmase, 
psühhiaatri poolt diagnoositud psühhoosiepisoodi avaldumine; ravimata psüh-
hoosi kestus alla 3 aasta; polnud varasemalt (kuni esmase psühhoosiepisoodini) 
saanud ravi antipsühhootikumidega. Patsiente ei kaasatud uuringusse, kui nad 
vastasid ühele järgnevatest väljaarvamiskriteeriumitest: muu meditsiinilise põh-
jusega psühhoos või uimastite /illegaalsete psühhoaktiivsete ainete tarvitamisest 
tingitud psühhoos. Esmase psühhoosiepisoodi diagnoos põhines kliinilisel 
intervjuul vastavalt Rahvusvahelisele Haiguste klassifikatsiooni 10. väljaandele 
(RHK-10). 
Kontrollgrupp kaasati uuringusse samast geograafilisest piirkonnast, kust 
esmase psühhoosiepisoodiga patsiendid, see koosnes 37 vaimselt tervest 
vabatahtlikust (16 meest ja 21 naist), kes statistiliselt ei erinenud vanuse ega soo 
poolest uuritavatest patsientidest. Kontrollgruppi valitud isikuid intervjueerisid 
kogenud psühhiaatrid, et välistada vaimsete häiretega isikute kaasamist. Välis-
tavaks tingimuseks oli kontrollgruppi kuuluvate isikute puhul ka psühhootiliste 
häirete esinemine nende lähisugulastel. Uuritavate kaasamise puhul ei olnud 
välistavateks kriteeriumiteks suitsetamine ja/või narkootikumide varasem 
tarvitamine anamneesis. 
Uuring koosnes kahest faasist: kaasamisperiood (haiglasse sattumisel) ja 
järelfaas (kestusega 7.18 ± 0.73 kuud). Esmase psühhoosiepisoodiga patsien-
tidel koguti tühja kõhuga võetud vereproovid, kliinilised ja demograafilised 
andmed ja kehamassiindeks (KMI) eelpool nimetatud kahel visiidil. Haigus-
sümptomite raskust hinnati kasutades Positiivsete ja negatiivsete sümptomite 
skaalat (PANSS). Füüsiline läbivaatus koosnes KMI hindamisest. Kontrollgrupi 
puhul koguti vereproovid, demograafilised andmed ning hinnati KMI. 
Biokeemiliste markerite määramisel kasutati tänapäevaseid rahvusvaheliselt 
aktsepteeritud määramismeetodeid [voogsisestusanalüüs (FIA, flow injection 
analysis), vedelikkromatograafia ja tandem-massispektomeetria kombinatsiooni, 
sandwich kemoluminestsents-immuunmeetodit ja fotokolorimeetria tehnikaid].  
 
 
Tulemused ja järeldused 
1. Ravieelselt oli esmase psühhoosiepisoodiga patsientidel võrreldes kontroll-
grupiga pikaahelaliste atsüülkarnitiinide (C14:1, C16, C16:1 and C18:1) tase 
seerumis tõusnud ja lühikeseahelalise atsüülkarnitiini (C3) tase langenud. 
Antipsühhootilise ravi tulemusena taandusid muutused atsüülkarnitiinide 
tasemetes kontrollgrupi tasemele. Erinevalt lühikeseahelalistest atsüülkarni-
tiinidest oli pikaahelaliste atsüülkarnitiinide teke karnitiini kaudu soodus-
tatud, mis viitab madalatasemelisele (low-grade) kroonilisele põletikulisele 
seisundile esmase psühhoosiepisoodiga patsientidel, mida aga seitsme-
kuuline antipsühhootiline ravi suutis korrigeerida/neutraliseerida. 
2. Võrreldes kontrollgrupiga oli esmase psühoosiepisoodiga patsientidel tõusnud 
teatud põletikumarkerite (ferritiini, PAI-1 ja IL-6) tase. Seitsmekuulise 
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antipsühhootilise ravi tulemusena langes patsientide grupis kõige enam 
ferritiini tase, millele järgnes IL-1α. Ferritiini, TNF-α, PAI-1 ja IL-6 tasemed 
taastusid kontrollgrupi tasemele, mis on tõenduseks madalatasemelisest 
kroonilisest põletikust esmase psühhoosiepisoodi ajal ning mille puhul anti-
psühhootiline ravi omas soodsat mõju põletiku neutraliseerimisel. 
3. Esmase psühhoosiepisoodiga patsientidel ei esinenud uuringusse kaasamise 
hetkel oksüdatiivse stressiga seotud parameetrites olulisi erinevusi võrreldes 
kontrollgrupiga. Seitsmekuulise antipsühhootilise ravi tulemusena vähenes 
patsientide grupis valkude ja lipiidide peroksüdatsiooni määr, mis on seos-
tatav antipsühhootikumide positiivse mõjuga üldisele oksüdatiivse stressi 
tasemele.  
4. Kokkuvõtvalt näitasid eelpool toodud tulemused seda, et esmane psühhoosi-
episood on seotud madalatasemelise kroonilise põletikulise seisundiga, 
millega kaasnevad muutused lipidoomikas (atsüülkarnitiinides), kuid samal 
ajal ei esine märkimisväärset erinevust oksüdatiivse stressi tasemes võrreldes 
kontrollgrupiga. Seitsmekuulise antipsühhootilise ravi tulemusena alaneb 
põletiku ja oksüdatiivse stressi tase ning muutused atsüülkarnitiinides 
normaliseeruvad kontrollgrupi tasemele. Vaatamata nimetatud positiivsetele 
toimetele, toob antipsühhootiline ravi juba haiguse varajases staadiumis 
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